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As rates of non-communicable disease such as diabetes mellitus raise the questions regarding how 
these diseases arise becomes more pertinent. One of the major causes of these types of disease is 
the effects of the modern diet which is typically high in nutrients including sugars, fats, purines 
and salt. Of these nutrients, the effects of high purines have been underrepresented in the current 
body of research. Increased dietary purines result in a commensurate increase in the synthesis of 
uric acid elevating serum uric acid level. This increase induces hyperuricemia and has been 
correlated through epidemiological studies to the development and progression of degenerative 
diseases including diabetes mellitus.  
In an attempt to shed light on the mechanism that underpins this effect we have elected to 
investigate the effects of hyperuricemic conditions on the viability and growth of pancreatic β-cells 
through the use of live cell assays to evaluate: cellular metabolism, cell count, autophagy, and 
apoptosis. To explain any changes in pancreatic β-cell viability and proliferation, we also 
investigated how the stability of a cellular growth and viability regulating protein, DEPTOR, may 
change under hyperuricemic conditions. We did this by directly measuring DEPTOR-bound 
ubiquitin though the use of co-immunoprecipitation. To explain any observed changes in DEPTOR 
ubiquitination we also investigated the expression of proteins responsible for DEPTOR 
ubiquitination, β-TrCP, and DEPTOR deubiquitination, USP3. Finally, we investigated if there 
was any direct interaction between DEPTOR and uric acid using co-immunoprecipitation to test 
for any potential bound uric acid as it may provide insights into any changes in DEPTOR 
ubiquitination, β-TrCP expression, or USP3 expression.   
As a result of this investigation, we found that hyperuricemic conditions are sufficient to cause 
significant reductions in pancreatic β-cell metabolism and cell mass and a significant increase in 
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autophagy and apoptosis. This was paired with an increase in DEPTOR stability arising from the 
observed reduction in DEPTOR-bound ubiquitin. This reduction in DEPTOR-bound ubiquitin was 
caused by a significant shift in the expression of β-TrCP and USP3 which resulted in a net shift in 
the balance if ubiquitination to favour the removal of ubiquitin over its binding. Additionally, our 
attempts to probe for potential DEPTOR-bound uric acid were successful and found that uric acid 
did in fact bind to DEPTOR and that this binding may explain what initiated the shifted balance of 
DEPTOR ubiquitination.  
These results have presented some interesting questions as they are the first to indicate: uric acid 
is capable of modifying DEPTOR ubiquitination, USP3 was identified as a new major regulator of 
DEPTOR stability within the pancreatic β-cell, uric acid as a possible new regulator of cell function 
that has as yet gone unnoticed, and finally the differences between mouse and human responses to 
hyperuricemia may provide new insights into the potential mechanism that underpins uric acid’s 
role in  the regulation of ubiquitination.  
In summary, in our attempts to better understand the causes of uric acid driven increases in diabetes 
mellitus risk we have found that hyperuricemic conditions are sufficient to reduce the function and 
mass of pancreatic β-cells and that this effect is caused by a previously undescribed uric acid-
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1.1 Uric acid  
1.1.1 Uric acid homeostasis 
In humans, uric acid is the final product of purine metabolism. It takes place in all cells as the 
regulation of purines is key to maintaining adequate regulation of DNA, RNA and ATP functions, 
however, uric acid is mainly synthesised in the liver from purines and the metabolism of dietary 
fructose (Fathallah-Shaykh & Cramer, 2014). As shown in figure 1 uric acid synthesis is performed 
by the enzyme xanthine oxidase (XO) which acts as a rate limiting enzyme (Maiuolo et al., 2016). 
Uric acid leaves the body by excretion via the kidney or the intestine. The kidney is an important 
regulator of circulating uric acid levels as it reabsorbs around 90% of filtered uric acid whilst being 
responsible for 60–70% of total body uric acid excretion (Bobulescu & Moe, 2012). This is 
achieved via uric acid transporters namely ATP-binding cassette superfamily G member 2 
(ABCG2), solute carrier family 2 member 9 (GLUT9), multidrug resistance-associated protein 4 
(MRP4), organic anion transporters 1-4 (OAT1-4), and solute carrier family 22 member 12 
(URAT1), all of which as shown in figure 2 are found within the proximal tubule, and act to 
maintain dynamic uric acid homeostasis (Wright et al., 2010). 
 
1.1.2 What is hyperuricemia and how does it arise? 
Hyperuricemia is a condition, defined clinically as a serum uric acid (SUA) level exceeding 6.5 
mg/dL (360µM) and can occur in many ways. The primary form as the more common form is due 
to increased purine metabolism and is resulting from dietary and lifestyle factors (So & Thorens, 
2010). Secondary hyperuricemia is caused by dysregulation of normal uric acid homeostasis due 
to diseases like chronic renal disease (Kelly et al., 1973), including increased xanthine oxidase 
function or changes in the function of excretory pathways. Primary hyperuricemia has seen a 
massive rise in recent years as modern diets with increased purine levels, sugars (particularly 
2 
 
fructose) and more sedentary lifestyles lead to growing incidence rates of hyperuricemia worldwide 
(Zhu et al., 2011).  
Considering this trend, there has been increased interest in studying the effects of hyperuricemia 
beyond uric acid crystallisation leading to gout. These studies focus primarily on how serum uric 
acid may modify existing cellular survival pathways such as how uric acid can increase autophagy 
through upregulation of Microtubule-associated proteins 1A/1B light chain 3B (LC3-II) (Sheng et 
al., 2017) and how it increases inflammatory response through the upregulation of nuclear factor-
κB (NF-κB) (Spiga et al., 2017). This research has prompted investigation into how the resultant 
changes induced by hyperuricemia may impact on diseases that arise from a diet similar to that of 
a high purine diet such as a high fat or high sugar diet, namely diabetes mellitus.  
 
 
Figure 1. A schematic representation of normal human uric acid homeostasis. 
In humans, uric acid is produced by the breakdown of purines which are obtained primarily through dietary intake. 
Purines metabolites are then converted to uric acid by the enzyme xanthine oxidase within the cell. The highest 
concentrations of xanthine oxidase is found in the liver. Following its synthesis uric acid is secreted into to the 
bloodstream where it accumulates and can be measured as serum uric acid. Uric acid levels within the serum are a 
result of the balance between its synthesis and excretion. The majority of the uric acid excretion is handled by the 
kidney which filters 70 - 80 % of the serum uric acid, of which 10 - 15% is excreted and the remaining 85 – 90% 







Figure 2. Uric acid transport. 
Illustration of the arrangement of key uric acid transporters in different tissues.  
The kidney is the major regulator of serum uric acid balance as a result of the balance between secretion and 
reabsorption. The liver is the major source of uric acid synthesis within the body but facilitates an alternative form 
of uric acid secretion through incorporation into the bile as it passes through the intestine. The pancreas provides an 
example of how other cells throughout the body may handle uric acid.  It is based on observations made in our 
previous work. 
 
      
          
            
      
      
      
      
      
      
      
   
   
      
     
         
        
                 
            
   
   
   
   
   
   
   
   
   
   
   




1.2 The pancreas 
The vast majority of endocrine cells in the pancreatic islets are β-cells (~70%) (Wang et al., 2013), 
which produce and secrete insulin in response to high plasma glucose concentrations. The high 
proportion of β-cells in the pancreas point to their crucial role as the primary glucose sensor in the 
human body. Optimal control of blood glucose levels depends on dynamic and responsive changes 
in insulin production and secretion by the pancreatic β-cells and their capacity for a large increase 
in secretion during feeding states. Unlike other cell types in the pancreas, such as α-cells, where 
the population of cells do not significantly change throughout life, the pancreatic β-cell population 
remains dynamic, depending on various factors such as age, body weight and metabolic status 
(Saisho et al., 2013). It has been shown that β-cell mass increases significantly around milestones 
that herald large growth periods i.e. infancy and puberty. This observation coupled with the 
analysis that β-cell mass increases proportionally to body mass indicates that the individual cells 
have a finite capacity for insulin secretion and as such maintaining the appropriate cell mass is key 
to maintaining insulin secreting capacity to cope with large increases in demand that may occur in 
the fed state.  
 
1.2.1 Diabetes mellitus 
As soon as the function or viability of the β-cells is compromised, the body is unable to release the 
amount of insulin necessary for adequate glucose homeostasis leading to the development of 
diabetes mellitus (DM, (Johnson et al., 2013)). DM is considered a global epidemic with over 400 
million diagnosed people, translating into almost 10% of the adult population (Jiang et al., 
2012)(Rojnic Putarek et al., 2015)(Schipf et al., 2014). DM is defined as the inability to adequately 
regulate blood glucose through insulin secretion. DM as a metabolic disease, particularly 
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detrimental in regard to both patient morbidity and mortality. This is due to the fact that although 
the initial symptoms are easily regulated as the disease progresses, it can rapidly induce multiple 
severe comorbidities such as kidney failure (Thomas et al., 2015), cardiovascular depression (Qiu 
et al., 2015), and peripheral neuropathy (Papanas & Ziegler, 2015). The disruption to adequately 
control glucose homeostasis has a major impact on multiple vital pathways such as glycosylation 
and glycation which in turn can have disastrous flow of effects affecting the regulation of healthy 
cell function (Ohtsubo & Marth, 2006). This is further compounded by the fact that as the disease 
progresses the damage to insulin secretion and receptor pathways is irreversible. After a certain 
point, patients are reliant on pharmaceutical regulation of serum glucose which lacks the dynamic 
responsiveness necessary to completely prevent further degradation and periodical dysregulation 
of serum glucose. This brings us to the largest problem DM presents to society as a whole, once 
this disease progresses past a certain point, patients become highly dependent on medication to 
maintain healthy serum glucose levels. The consequences are two-pronged effects of often leaving 
patients with a lower quality of life (Frøisland et al., 2013), and of putting large strain on medical 
resources as disease progression requires more intensive interventions as more detrimental co-
morbidities arise (Chevreul et al., 2014)(Huber et al., 2014). 
  
1.2.2 Type-1 diabetes mellitus  
Type-1 diabetes mellitus (T1DM) is well established as an autoimmune disorder which results in the 
destruction of pancreatic β-cells. Development of T1DM is strongly influenced by a genetic 
component, with the majority of T1DM cases being diagnosed during childhood or early adulthood 
(Olmos et al., 1988). However, there is an increasing prevalence of evidence to suggest the involvement 
of environmental factors in the development of T1DM. The best evidence to support this theory comes 
from studies involving identical twins in which one twin presents with T1DM, however, contrary to 
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what we would expect to see if this condition was driven purely by genetic factors, only between 30-
50% of the twins both presented with T1DM. This fact strongly indicates the involvement of 
environmental factors and/or cues, in combination with genetic factors, however, the environmental 
cues remain elusive (Olmos et al., 1988). The defining characteristic of T1DM is the chronic, 
progressive destruction of pancreatic β-cell mass by an auto-immune response resulting in the inability 
to secrete sufficient insulin but patients retain normal insulin sensitivity as insulin receptors throughout 
the body remain unaffected (Pipeleers et al., 2008).  
 
1.2.3 Type-2 diabetes mellitus 
Type-2 diabetes mellitus (T2DM) is by far the most prevalent form representing over 90% of all DM 
cases, and its prevalence has reached epidemic proportions worldwide (Wu et al., 2014). The exact 
cause of T2DM is insufficiently understood, however, there is an overwhelming consensus that the 
changes in the modern diet and lifestyle and the accompanying metabolic stress have been the key 
contributing factors in T2DM development (Low et al., 2015). Despite the fact that the cause resulting 
in the development of T2DM may differ between patients, the ultimate hallmark of chronic 
hyperglycaemia in T2DM is known to be caused by the impaired insulin secretion and insulin resistance 
(Johnson et al., 2013). The currently proposed model of T2DM pathogenesis is based on the initial 
development of peripheral insulin resistance which over time leads to down-regulation of insulin 
receptors, leading to increased insulin secretion to the detriment of pancreatic β-cell survival and 
functional capacity (Johnson et al., 2013). T2DM is far harder to treat than T1DM as the resistance to 
insulin signalling makes using endogenous regulatory pathways for intervention more difficult. The 
most common form of treatment is to regulate initial glucose metabolism from dietary factors by 
altering glucose consumption within the diet or by altering glucose handling in the body through 
drugs such as metformin (Vijayakumar et al., 2017). These existing treatments have shown to be 
effective when paired with dietary and lifestyle changes. However, they are most effective if T2DM 
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is detected in the early stages as the impact on the quality of life has resulted in poor adherence 
rates for treatments reducing the overall effectiveness of treatment. 
 
1.3 Uric acid and Diabetes mellitus progression 
Numerous studies have investigated the potential correlation between two of the world’s rising 
dietary driven health complications, hyperuricemia and diabetes mellitus. Studies in both young 
and old populations spanning up to 15 years have found a significant increase in the risk of 
developing diabetes in patients presenting with hyperuricemia. These studies have gone as far as 
to suggest that hyperuricemia causes a 27% increase in risk of developing diabetes (Krishnan et 
al., 2012; Musacchio et al., 2016) and that 1 in 11 new cases of diabetes could be attributed to this 
(Krishnan et al., 2013).  
This correlation is further supported by the mechanisms of reduced cellular viability described 
within previous research looking into the effects of uric acid within other parts of the body. The 
main hallmarks of T2DM development and progression are loss of viable pancreatic β-cell mass 
and peripheral insulin resistance. Both these effects have been described in experiments performed 
by Shimodaira et al., 2014, Spiga et al., 2017, Li et al., 2018, Jia et al., 2013 in which they were 
either induced or exacerbated by hyperuricemic conditions. As shown in previous studies the 
increase in autophagy as a result of increased mTOR inhibition and pro-autophagy protein 
activation alone could easily explain the initial loss of pancreatic β-cell mass or provide a means 
for progressive loss as a result of chronic exposure. This observation when also paired with the 
observed decreases in insulin sensitivity in peripheral tissues as a result of the inflammation that 
may arise due to increased uric acid generated damage associated molecular pattern (DAMP) 






The mechanistic target of rapamycin (mTOR) protein complexes C1 and C2 are major cellular 
regulators of pathways involved in cell metabolism, growth, proliferation and survival (Saxton & 
Sabatini, 2017). Activation of mTORC1 via amino acids or growth factors facilitates protein, lipid 
and nucleotide synthesis and consequently cell growth, whereas an inhibition of mTORC1 as a 
consequence of cellular stress or just starvation induces autophagy, a process regulating turnover 
of proteins or organelles in order to generate energy for cell survival. A disturbance of this pathway 
can lead to cell death (Vergès & Cariou, 2015). The regulation of mTORC2 is only beginning to 
be discovered, but the available evidence seems to suggest that only growth factors directly regulate 
this complex. Recent findings have revealed novel important roles for mTORC2 in the 
phosphorylation of AGC kinase family members such as protein kinase C (see figure 3) (Cameron 
et al., 2017).  
Although these complexes have distinct and different targets their method through which they 
activate their targets is the same. This activation is achieved through the function of mTOR as a 
serine/threonine protein kinase which directly phosphorylates target proteins leading in most cases 
to the activation of downstream pathways (Varusai & Nguyen, 2018). As such, their function is 
largely defined by their interaction with a regulatory-associated protein of mTOR (RAPTOR) in 
the case of mTORC1 or rapamycin-insensitive companion of mammalian target of rapamycin 
(RICTOR) in the case of mTORC2. These proteins differentiate the complexes and regulate which 
target proteins they can interact with. A protein that binds and negatively regulates both mTOR 
complexes in a mutual relationship is DEP domain-containing mTOR-interacting protein or 
DEPTOR for short (Catena & Fanciulli, 2017). Due to the fact that the mTOR complexes are 
involved in major cell processes, which determine cell health and survival, the impact of DEPTOR 
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and the regulation of its turn-over via ubiquitination are currently hot topics in cancer and diabetic 
research (Catena & Fanciulli, 2017).  
 
1.5 DEPTOR 
DEPTOR is a product of the DEPDC6 gene which codes for a protein with tandem N-terminal 
DEP (Dishevelled, Egl-10, Pleckstrin) domains and a C-terminal PDZ (Postsynaptic density 95, 
Discs large, Zonula occludens-1) domain (Jemth & Gianni, 2007). Due to the lack of previous 
studies into the function of the DEPDC6 gene product, it was named DEPTOR in reference to its 
DEP domains and its specific interaction with the mTOR core unit. Experiments confirmed that 
the endogenous mTOR core unit was specifically co-immunoprecipitated with DEPTOR and was 
confirmed using both RAPTOR-based and RICTOR-based immunoprecipitations. These were 
used to confirm the binding of DEPTOR to both mTOR complexes as mTOR complexes are 
defined by their binding to RAPTOR in the case of mTORC1 and RICTOR in the case of mTORC2 
(Fig. 3). Initial studies were performed to investigate if DEPTOR interacted with mTOR and/or 
mLST8, the only protein common to both mTORC1 and mTORC2. Reciprocal experiments 
showed that the PDZ domain of DEPTOR mediates its interaction with mTOR. 
In terms of function, DEPTOR directly suppresses mTOR by interacting with the FAT domain of 
the mTOR core unit via a PDZ domain located at its C-terminus (Peterson et al., 2009). It results 
in the inability of binding of key mTOR substrates resulting in functional inhibition of both mTOR 
complexes and consequently a reduction in cell metabolism, growth pathways and proliferation 
pathways. It is coupled with the upregulation of autophagic activity resulting in large scale 
suppression of cellular energy demand, function and viability. This leads to its role in disease 
pathology which has focused on cancer. In this case, most studies have shown the major decrease 
in DEPTOR expression leads to increased rates of tumour growth and survivability in breast, 
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pancreatic, and prostate cancers, however, this trend is reversed in thyroid cancers (Catena & 
Fanciulli, 2017). This difference between different cancers is explained as being a result of a 
proposed protection form endoplasmic reticulum stress in these cells as only cells characterised 
with high protein synthesis and expression show this inverse response to DEPTOR (Catena & 
Fanciulli, 2017). Additionally, DEPTOR is thought to act as a key metabolic regulator as it has 
been shown that within the liver it functions to accelerate the shift towards a fasting response when 
the body is put under starvation conditions. DEPTOR’s proposed function further promotes the 
idea that DEPTOR is a low energy state driven protein synthesis and cell growth regulator (Caron 
et al., 2017). 
This feeds into the understanding of the regulation of DEPTOR. According to the current 
understanding, DEPTOR and the mTOR complexes are engaged in a dynamic inhibition loop in 
which DEPTOR is both able to inhibit the mTOR complexes but is also inhibited by them as 
illustrated in figure 3. Although the finer details what determines the directionality is unclear, the 
current understanding indicates extracellular environmental factors dictate the stability of 
DEPTOR and the rate at which it is degraded as a result of ubiquitin signalling. An explanation is 
provided by the previous observations, why DEPTOR activity is greatest under starvation or low 
energy conditions as this would allow for the body to down-regulate energy demand by down-
regulating the mTOR complexes. Hence, DEPTOR presents as a prime candidate for my study as 
it provides a potential link between the changes we see in the cellular environment in conditions 








Figure 3. A. mTOR function under normal conditions. B. Proposed uric acid driven 
DEPTOR activation.  
(A) This figure shows the known function of the mTOR complexes under physiological normal conditions. 
Through their activation due to multiple nutrient based factors the mTOR complexes are responsible for the 
phosphorylation and activation of multiple substrates that are key for the maintenance of several cellular functions. 
(B) A proposed model for the activation of DEPTOR by uric acid is illustrated. Under these conditions, we propose 
that the increase in serum uric acid leads to increased DEPTOR stability. This inhibits the function of the mTOR 
complexes and leads to alteration in cellular function as a consequence.  
 
                
       
       
       
      
     
       
         
  
            
                
       
  




















1.6 Ubiquitination of proteins and DEPTOR 
Ubiquitination is a post-translational protein modification which determines the fate/degradation 
of proteins via the proteasomal pathway (Heideker & Wertz, 2015). It is dependent on the 
interaction between two processes, the ubiquitination and deubiquitination facilitated by respective 
enzymes. The ubiquitination cascade has three major components: the first component is E1 or 
ubiquitin activating enzyme. E1 is responsible for the binding of free ubiquitin which is bound to 
E1 along with ATP activating ubiquitin (Neutzner & Neutzner, 2012). Following this, E1 transfers 
the bound ubiquitin to E2 or ubiquitin conjugating protein (Zhang & Sidhu, 2014). E2 then carries 
the ubiquitin until it binds to E3 or ubiquitin ligase. The E3 ligase is the most specific of the three 
components of the ubiquitination cascade and is responsible for binding to specific target proteins. 
It transfers the ubiquitin from E2 to the target protein resulting in ubiquitin-tagging of the protein 
and the degradation or trafficking of the target protein (Berndsen & Wolberger, 2014). Because E3 
ligases are the most specific component of the ubiquitination cascade they provide the best target 
for treatment as their specificity reduces the potential of off target effects and interference due to 
unexpected alterations of non-target proteins.  
This specificity arises due to the interactions between unique binding sites found on an E3 ligase 
and the corresponding domain on a target protein. This also allows for a temporal sequence as this 
binding site may be internalised within the protein’s folding structure until the addition of a 
posttranslational modification leads to a conformational change in protein folding allowing for 
interactions with a respective E3 ligase. It should also be noted that there are different types of 
ubiquitination varying based on the number of bound ubiquitin and their arrangement leading to 
mono- or polyubiquitination. This difference in number and arrangement allows for multiple 
possible ubiquitin signals and is one of the underpinning principles in the ideas regarding 
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ubiquitin’s role as a multi-destination protein trafficking signal. As this process is dependent on 
the specific interaction between a protein and its E3 ligase this process can be disturbed through 
either the addition of post-translational modifications that prevent the externalisation or actively 
internalise the domains necessary for recognition and interaction with an E3 ligase or through 
reduction in the availability of the ligase itself (Liu et al., 2015). 
In addition to this, as we discussed the number and distribution of bound ubiquitin is also key to 
regulating the consequences of ubiquitination, as such anything that would reduce the number of 
or change the arrangement of the bound ubiquitin in a polyubiquitin chain would have massive 
impacts on the proteins turnover or trafficking (Ohtake et al., 2015). Ways in which this may occur 
include the limitation of available ubiquitin or through the addition of molecules to the bound 
ubiquitin that modify the ubiquitin chain structure by either altering the bond structure or through 
simply premature termination of a polyubiquitin chain such as the process of acetylation (Ohtake 
et al., 2015). To investigate uric acid’s role as a potential modulator of this process, we will be 
examining DEPTOR’s E3 ligase, beta-transducin repeat containing protein (β-TrCP). This would 
explain previously observed changes to DEPTOR stability as inhibition of an E3 ligase would 
result in the reduction of protein degradation (Zhao et al., 2005). 
 
1.6.1 β-TrCP 
We have chosen to focus on beta-transducin repeat containing protein (β-TrCP) as this is the known 
E3 ligase of DEPTOR (Zhao et al., 2005), and as such any alteration to its expression would have 
a direct impact on DEPTOR ubiquitination resulting in changes in protein levels. 
β-TrCP belongs to the F-box family of proteins, which forms a multicomponent Skp1/Cul1/F-box 
protein (SCF) ubiquitin ligase complex with the β-TrCP complex functioning as the target 
recognition subunit. As a general role β-TrCP functions to regulate cell survival and turnover rates 
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thought regulating the turnover of key proteins. Examples of these proteins include nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2), NF-κB, and mammalian period-1 protein (PER1). Nrf2 controls 
the expression of genes that participate in biotransformation reactions, redox homeostasis, 
energetic metabolism, DNA repair, and proteostasis (Cuadrado, 2015). NF-κB, as stated 
previously, is key to immune and inflammation response and is controlled by ubiquitination via β 
-TrCP (Melikian et al., 2017). Additionally, PER1 is a key clock gene responsible for maintaining 
circadian rhythm (Yang et al., 2009), and as a consequence of this regulates mild fluctuations in 
full body metabolic process. These are just some of a growing list of identified downstream β-TrCP 
ubiquitin substrates, implicating a critical role for β-TrCP in regulating both, cell cycle progression 
and cellular survival.  
β-TrCP as the ubiquitin ligase for DEPTOR works by ubiquitinating DEPTOR in the c-terminus 
domain. This ubiquitination is triggered in response to the phosphorylation of DEPTOR at Ser293 
and Ser299 by the mTOR complexes. This has been confirmed through the use of β-TrCP siRNA 
and targeted DEPTOR point mutations, both of which confirmed that when β-TrCP expression or 
binding was inhibited DEPTOR became more stable leading to reduced mTOR function and 






Figure 4. DEPTOR regulation via mTOR.  
This figure shows how DEPTOR is phosphorylated by mTOR leading to β-TrCP-mediated ubiquitination and 




The counter to the ubiquitination cascade is the activity of deubiquitinating enzymes, DUBs also 
called ubiquitin specific proteases (USPs). There are two main classes of DUBs/USPs, cysteine 
proteases and metalloproteases. Although these two classes achieve this differently, the primary 
function of a DUB/USP is to cleave the peptide bond between ubiquitin and the protein it is bound 
to thus removing the ubiquitin from the protein and preventing its degradation (Heideker & Wertz, 
    
      
 
 
      
 
         
  
      
           
  
 
       
         
     
      
  
       
       




2015). USP’s function through cleavage of the isopeptide bond at C-terminal glycine residues of 
ubiquitin. These ubiquitinyl bonds can be generated at the N-terminus of another ubiquitin 
molecule, the side chain of lysine in another ubiquitin molecule or to the side chain of a lysine 
residue in another protein (Heideker & Wertz, 2015).  
Despite a strong homology observed between USP, recent three-dimensional structural imaging of 
several USPs reveal striking differences in the accessibility to the catalytic pocket pointing to 
potentially high specificity (Daviet & Colland, 2008). Although the key DUB/USP for DEPTOR 
has yet to be confirmed, initial studies have demonstrated that the action of deubiquitinases 
including ovarian tumour domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) and 
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) can lead to alterations in DEPTOR 
expression, and that this is significant enough to alter the regulation of mTOR (Zhao et al., 2018). 
Due to the fact that alterations of the expression of a DUB have a large impact on protein function 
any potential DUB cannot be ignored. 
 
1.7.1 USP3 
Recent studies have shown some potential candidates for a DEPTOR deubiquitinase. These studies 
have shown multiple potential deubiquitinases interact with DEPTOR indicating that they may 
have different functions (Zhao et al., 2018). This difference in function is most likely due to having 
different activation conditions or pathways. However, when we began this study the work by Zhao 
and co-workers had yet to be released. As such the selection of the Ubiquitin specific protease 3 
(USP3) was made based on the fact that it is highly expressed in the pancreas (Santin et al., 2012; 
Gorelik & Sido, 2017) and has been shown to be involved in diabetic neuropathy in multiple 
regions in the body (Goru et al., 2017). This combined with the fact that USPs can not only remove 
all protein bound ubiquitin but also degrade polyubiquitin chains means that any changes in USP3 
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expression could lead to changes in DEPTOR degradation. This could occur through the complete 
removal of ubiquitin bound to DEPTOR, or through significant degradation of any polyubiquitin 




Autophagy is the process by which the cell breaks down damaged proteins, misfolded proteins, 
damaged organelles or certain overexpressed proteins to provide additional energy. In healthy cells, 
this process is tightly controlled, and in addition to providing energy, it also functions to remove 
enzymatic or regulatory proteins that are overexpressed for current cell function (Ravanan et al., 
2017). Autophagy can take place as a result of many pathways, however, they can largely be 
defined and categorised as microautophagy which involves the incorporation of small regions of 
the cytosol into a lysosome degrading small soluble proteins distributed within the cytosol. 
Chaperone mediated autophagy (CMA) which uses specific chaperone molecules to transport 
specific single proteins to digestive vesicles. Macroautophagy involves the enveloping of targets 
in a double membrane which is then fused with lysosomes to form an autolysosome. 
Macroautophagy targets larger proteins, insoluble proteins and organelles. Although all of these 
forms of autophagy have different targets, they are all largely responsive to the same triggers being 
starvation or cellular stress. These pathways are active in cells under non-stress conditions as they 
provide the necessary degradation to maintain healthy protein turnover by removing damaged or 
decayed proteins (Takahiro Shintani & Klionsky, 2004).  
Although all types of autophagy are important, this study be will focusing on macroautophagy for 
two reasons: Firstly, out of all the types of autophagy macroautophagy has the greatest potential 
impact for change while still being easy to measure. This is due to the fact that microautophagy 
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has a lower impact at equal levels of activity and CMA has a high degree of specificity making it 
more difficult to take general measurements in change of activity. Secondly, macroautophagy is 
regulated by mTOR, and this is due to the fact that multiple autophagy regulating pathways are 
controlled at some level by mTORC1 including, phosphoinositide 3-kinase (PI3K) which is 
important for target recognition and Unc-51 like autophagy activating kinase (ULK1/2) which is 
responsible for signalling the initiation of autophagic vesicle formation (Sheng et al., 2017). 
Following the signalling from ULK1/2, the formation of the autolysosome is regulated by several 
proteins including microtubule-associated proteins 1A/1B light chain 3B (LC3 II). LC3 functions 
both as a regulator of autophagosome formation but also as a marker of autophagosome maturation 
(Huang & Liu, 2015).  
Although autophagy is necessary for the normal function of a cell if it becomes disturbed it can 
lead to massive loss of function as excessive protein degradation results in the disruption of key 
protein cascades. If autophagy is not brought back to healthy levels within a sufficient timeframe 
the effects of excessive protein degradation can trigger programmed cell death or apoptosis (Lõpez 
De Figueroa et al., 2015). 
 
1.9 Aims and research objectives 
The aim of this study was to determine the involvement of the mTOR complexes in the loss of 
pancreatic β-cell mass under hyperuricemic conditions via the regulation of DEPTOR. 
To determine the exact mechanism, how uric acid regulates DEPTOR turn-over, we will examine 
whether hyperuricemic conditions induce any changes in DEPTOR ubiquitination, which is a 
hypothesis based on previous results. A change in ubiquitination of DEPTOR can have several 
reasons: 1) a change in the DEPTOR-specific ubiquitin ligase expression, namely E3 ubiquitin 
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ligase β-TrCP; 2) a change in the ubiquitin specific protease, possibly USP3, expression; 3) by 
direct modification of DEPTOR by uric acid. 
 
1.9.1 Hypothesis 
We hypothesise that hyperuricemia reduces the ubiquitination of DEPTOR and that a change in 
expression of the E3 ubiquitin ligase β-TrCP or the deubiquitinase USP3 is responsible for this 
change of DEPTOR ubiquitination. Furthermore, we hypothesise DEPTOR not to be modified 
directly by uric acid. As a result of this activation of DEPTOR, the subsequent inhibition of mTOR 




FIGURE 5. Hypothetic Model.  
Increased serum uric acid as a result of increased dietary purines alters DEPTOR ubiquitination within pancreatic 
β-cells. This leads to a loss in cell viability due to decreases in cellular metabolism and growth and increases in 
cellular autophagy as a result of changes to mTOR activity. This change in mTOR activity is the result of changes 
in DEPTOR ubiquitination. 
 
     
      
          
           
       
 
                   
  
  
              
         
        
          
        
             
  
       













2.1 Cell lines 
2.1.1 Human 1.1B4 cells 
1.1B4 is an immortalised hybrid cell line formed by the electrofusion of a primary culture of human 
pancreatic islet cells with human ductal carcinoma cells. 1.1B4 cells were used as an alternative 
functional model of a human pancreatic β-cell, due to the low availability of human primary cells. 
Furthermore, functional assessments have shown 1.1B4 cells exhibit a similar cellular response 
and changes in gene expression, in response to varying extracellular glucose concentrations, to 
primary pancreatic islets (McCluskey et al., 2011). 1.1B4 cell line was used as a human cell model 
of a pancreatic β-cell, allowing the results of this study to be more relatable in terms of studying 
the component of hyperuricemia in human type-2 diabetes mellitus development. 
 
2.1.2 Mouse MIN6 cells 
MIN6 cells originate from a transgenic C57BL/6 mouse insulinoma expressing an insulin-
promoter/T-antigen construct. They form islet-like cells. MIN6 cells express GLUT-2 and 
glucokinase and respond to glucose within the physiological range (Miyazaki et al., 1990). They 
are used regularly throughout contemporary literature and are the most common mouse cell line 
used in the research of diabetes when a mouse model is required.  
 
2.2 Cell Culture, Harvest and Treatment 
2.2.1 Cell culture 
2.2.1.1 1.1B4 culture 
1.1B4 cells were cultured and maintained in Roswell Park Memorial Institute medium (RPMI-
1640, SIGMA®) with 11mmol/L glucose, 10% FBS, 100U/mL penicillin G sodium, 100μg/mL 
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streptomycin sulfate at 37°C and 5% CO2. The medium was supplemented with 2g/L NaHCO3 and 
brought to a pH of 7.4. Passages 30-70 were used for all cellular experiments. Cell lines were 
passaged once a confluence of approximately 85% or greater was achieved by washing with 
phosphate-buffered saline (PBS: 137mM NaCl, 2mM KCl, 10mM Na2HPO4 and 1.8mM KH2PO4) 
prior to detachment with 0.25% (w/v) trypsin (TrypLE™ express; life technologies®) and splitting 
at a 1:10 ratio.  
 
2.2.1.2 MIN6 culture 
Mouse insulinoma (MIN6) cells were cultured and maintained in Dulbecco’s modified eagle’s 
medium – high glucose (SIGMA®), 10% FBS, 100U/mL penicillin G sodium, 100μg/mL 
streptomycin sulfate at 37°C and 5% CO2. The medium was supplemented with 3.4g/L NaHCO3, 
5µL/L of β-mercaptoethanol and brought to a pH of 7.4. Cell lines were passaged once a confluence 
of approximately 80% or greater was achieved by washing with phosphate-buffered saline (PBS: 
137mM NaCl, 2mM KCl, 10mM Na2HPO4 and 1.8mM KH2PO4) prior to detachment with 0.25% 
(w/v) trypsin (TrypLE™ express; life technologies®) and splitting at a 1:5 ratio. 
 
2.2.2 Treatment 
2.2.2.1 Uric acid stock solution 
A uric acid stock solution was prepared at the concentration of 5mM, dissolving uric acid sodium 
salt (SIGMA®) in 1M sodium hydroxide (NaOH), brought to a pH of 7.4 using 1M hydrochloric 
acid (HCl) and final volume was adjusted using PBS.  
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2.2.2.2 Generation of samples  
For the generation of cell samples for co-immunoprecipitation and western blotting, 1.1B4 and 
MIN6 cells were harvested when they reached greater than 80% confluence in a 25cm2 flask. Cells 
were then seeded into 6-well plates at a density of 1x104 for 1.1.B4 and 5x104 for MIN6 cells. Cells 
were incubated in their respective medium for 24 hours prior to any treatment to allow cell 
adhesion. Cells were cultured for an additional 72 hours in their respective conditions. 300μM uric 
acid represents a physiologically normal condition for 1.1B4 cells, while 500μM represents a 
hyperuricemic condition, with an additional flask of cells left untreated to act as a control.  
 
2.2.3 Harvesting of cell samples  
Following 72 hours of treatment, all medium from each well was aspirated and the cells in each 
well were washed in sterile PBS to remove any dead cell debris and trace of compounds used 
during conditioning.  
 
2.3 Protein analysis 
2.3.1 Extraction of protein for western blot analysis 
To facilitate the analysis of the expression of our target proteins the total cellular protein had to be 
extracted from the cultured and treated cells. To minimise any protein degradation, the protein was 
extracted directly from 6-well plates containing the treated cells. To lyse the cells and liberate the 
protein the cells were bathed in 100µL of radioimmunoprecipitation (RIPA) buffer, containing a 
protease inhibitor cocktail (ThermoFisher Scientific™). The resulting lysate was collected into a 
2mL Eppendorf tube and centrifuged at 13,000 rpm for 5 minutes at 4°C to ensure maximal 
separation of cell debris and proteins solution. The supernatant containing the protein extract was 
transferred to a fresh Eppendorf tube. Following this, the extracted protein concentration was 
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measured against a known BSA (bovine serum albumin) standard using Bio-Rad DC™ protein 
assay (Bio-Rad®) and then stored at -20°C until needed. 
 
2.3.2 Extraction of protein for Co-immunoprecipitation analysis 
To allow us to detect the changes in DEPTOR bound proteins a co-immunoprecipitation is 
required. To facilitate this, proteins were extracted from treated cells in a way to maintain as 
accurate representation of protein to protein bonds as possible. To this end the treated cells as 
obtained in section 2.2.3 were bathed in 100µL of a specialised, preheated PBS based lysis buffer, 
containing 1% SDS and 10µM carbobenzoxy-Leu-Leu-leucinal (MG-123, Sigma-Aldrich) which 
is a proteasome inhibitor that has been shown to improve the preservation of protein ubiquitination. 
This mix was then passed 5-times through a 22-gauge needle and diluted with an equal volume of 
a TBS + 0.4% Triton X-100 to ensure a constant viscosity that would be suitable for the later stages 
of co-immunoprecipitation. This lysate was then immediately measured against a known BSA 
standard using Bio-Rad DC™ protein assay (Bio-Rad®) to determine its concertation; after this, 
the protein extract was immediately subjected to the protein isolation procedure outlined below.  
 
2.3.3 Target protein isolation 
To isolate the target protein (DEPTOR) from the total protein extract the target protein must be 
marked and separated from all other proteins present. This was achieved by first incubating 100µg 
of whole cell protein with 2µL of a mouse based DEPTOR antibody (ab103298) for 2 hours at 
room temperature on a shaker table. This allowed the antibody to bind to the target protein 
providing a means by which to isolate it from the total protein extract. Following this, 30µL of IgG 
sepharose protein beads (Sigma-Aldrich) and left to incubate for 1 hour at room temperature on a 
shaker table. This provides a matrix for the antibody-bound DETPOR to anchor itself to during the 
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removal of the remaining total protein extract. Once this is completed, any unbound proteins are 
washed away from the IgG beads using a 4 x PBS washes leaving only the bound DEPTOR 
remaining. Finally, to release the bound DEPTOR from the IgG beads 30µL of 5 x loading buffer 
(0.25% bromophenol blue, 0.5 M DTT, 50% glycerol and 10% Tris-HCl) was added to the beads 
and the sample was heated at 95°C for 5 minutes and afterwards used for gel electrophoresis as 
outlined below.  
 
2.3.4 Gel-electrophoresis and membrane transfer 
To image the levels of protein, proteins need to be separated by weight to allow for the visualisation 
of different proteins. This is the same for both the standard western blot and the co-
immunoprecipitation which was achieved using the method below. In the case of the western blot 
10μL of 5 x loading buffer (0.25% bromophenol blue, 0.5M DTT, 50% glycerol and 10% Tris-
HCl) was added to 100μg protein of the protein samples that we created in 2.3.1, these were 
incubated at room temperature for 5 minutes. Samples were then loaded onto a 12% SDS-PAGE 
(SDS-Polyacrylamide Gel Electrophoresis) gel. For molecular weight estimation, 7μL of Precision 
Plus Protein™ standard (Bio-Rad®) was loaded into the first well of the gel which was then run at 
120V for 90 minutes.  
To allow for the proteins to be detected, they need to be exposed to antibodies. As a means to 
facilitate this, the proteins were transferred from the gel to a PVDF membrane (Immobilon®) using 
a ‘semi-wet’ transfer protocol which entailed sandwiching the gel and the membrane between four 
layers of in transfer buffer (25mM Tris, 192mM glycine, 20% v/v methanol and pH ~8.3) saturated 
filter paper and being exposed to a directional current of 25V and 1.2A for 30 minutes using the 
turbo blotting system (Bio-Rad®).  
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Once the proteins were transferred onto the membrane, a 5% non-fat milk blocking buffer (5% 
non-fat milk powder in PBST) was introduced for 1 hour at room temperature whilst the blocking 
buffer and membrane were agitated by a shaker table. In the case of the co-immunoprecipitation, 
the same steps as above were used with the exception of the addition of 10μL of 5 x loading buffer 
(0.25% bromophenol blue, 0.5 M DTT, 50% glycerol and 10% Tris-HCl) as the appropriate amount 
of loading dye had already been added as a part of the protein isolation preparation described in 
2.3.3. 
 
2.3.5 Protein detection and imaging of the membrane 
To detect our target proteins, the membranes on which we had transferred our proteins onto were 
first exposed to a target specific antibody and then incubated overnight at 4°C on a tilt table, the 
concentrations for these antibodies can be seen below in table 1. Following this, the blots were 
washed four times for 10 minutes in PBST to remove any unbound primary antibody; then they 
were incubated in secondary antibody for 1 hour at room temperature on a shaker table. Once this 
had been completed, the blots were washed two-times in PBST for 10 minutes and two times for 
ten minutes in PBS to remove excess secondary antibody. Following this, the blots were imaged 
using the Syngene Pxi4 (Integrated Scientific Solutions Inc.) imaging system to detect the 
fluorescence of the secondary antibodies. Once the target was imaged, the blot was then stripped 
using a mild stripping buffer (15g glycine,1g SDS, 10mL Tween20, pH 2.2) and re-imaged to 
confirm that the previous signal was removed. Following this, the membranes were reincubated 
with the primary antibodies that were used to detect the proteins being used as loading controls, 
DEPTOR, for the co-immunoprecipitation and GAPDH for the western blots. It should be noted 
that in the case of the co-immunoprecipitations both ubiquitin and uric acid were imaged on the 
same blot as the difference in secondary antibody means that they could be determined by the use 
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of a specific stimulus frequency thus reducing the need to strip the blot an additional time with the 
hopes that this will help to preserve the more delicate signal of the bound proteins. 
 
2.3.6 Western blot analysis 
Once the blots had been imaged the resulting bands of fluorescent response were analysed using 
the software Image J (National Institutes of Health and the Laboratory for Optical and 
Computational Instrumentation). This system analyses the intensity of the bands using relative area 
density (RAD) to generate a numerical representation of the expression. This was then used to 
calculate the relative expression of proteins. In the case of the western blot data, the data was 
normalised to the untreated cells first as this provides a common denominator between the two cell 
types, then these ratios were corrected based on how the GAPDH values of the treated cell groups 
differed from the untreated cells so as to normalise against any shift that may be due to errors in 
protein loading.  
In the case of the co-immunoprecipitations, the math that produced the expression ratios was the 
same but DEPTOR was used to normalise instead of GAPDH because first there was no GAPDH 
to measure, second as DEPTOR was the TARGET of the co-immunoprecipitation. Using DEPTOR 
as a loading control ensured that we have equal amounts of DEPTOR present to ensure an accurate 
representation.  
 
Table 1. Target antibody conditions.  













USP3 Rb α USP3 1 :1,000 overnight ab101473 G α Rb 1: 10,000 1 hour SA5-10036 
β- TrCP M α β-TrCP 1 :500 overnight sc-390629 G α M 1: 5,000 1 hour 35518 
DEPTOR Rb α DEPTOR 1 :1,000 overnight ab103298 G α Rb 1: 10,000 1 hour SA5-10036 
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GAPDH Ch α GAPDH 1 :1,000 overnight ab83956 G α Ch 1: 10,000 1 hour ab175779 
 
Ubiquitin M α Ubiquitin 1 :1,000 overnight sc-8017 G α M 1: 5,000 1 hour 35518 
Uric Acid Rb α Uric 
Acid 
1: 1,000 overnight ab53000 G α Rb 1: 10,000 1 hour SA5-10036 
 
2.4 Live cell viability 
2.4.1 Cellular metabolism 
MTT assay is a colorimetric assay for assessing the cells’ metabolic activity and quantification of 
the relative viability of cells. Intracellular mitochondria exhibit NADH-dependent cellular 
oxidoreductase enzyme, which reduces the tetrazolium dye MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide) to insoluble, purple formazan. By solubilising and measuring the 
amount of formazan, this allows the relative quantification of the number of viable, proliferative 
cells, as cytotoxic cells undergoing cell death or cytostatic cells that are less proliferative express 
lower amounts of functional mitochondria that exhibit the NADH-dependent cellular 
oxidoreductase enzyme.  
For MTT assays, 1.1B4 and MIN6 cells were harvested when flasks reached 80% confluence or 
greater and were seeded onto 96-well plates at 2 x104 cells per well. After this, cells were incubated 
for 72 hours with 300μM uric acid representing a physiologically normal condition, and 500μM 
representing a hyperuricemic condition, with wells of cells left untreated to act as a control. 
Following treatment with their appropriate conditions, media was aspirated and 100µL of fresh 
media was added. In addition to this, 10μL/well of 5mg/mL MTT solution (final MTT 
concentration of 0.5mg/mL) was added and the cells were incubated for 4 hours at 37°C. Following 
incubation, 85μL/well of MTT solution was removed and 50μL/well of DMSO was added to 
dissolve the formazan crystals produced by mitochondrial respiration. DMSO in each well was 
thoroughly mixed by repeated pipetting and then the plate was incubated for an additional 20 
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minutes at 37°C. Dissolved formazan in each well was quantified via absorbance values measured 
at 540nm with a BioTek® Synergy 2 multi-mode microplate reader. 
 
2.4.2 Autophagy Assay 
Autophagy Detection Kit (ab139484) measures autophagic vacuoles and monitors autophagic flux 
in live cells by using a cationic amphiphilic tracer (CAT) dye that rapidly partitions into cells 
labelling of vacuoles associated with the autophagy pathway.  
1.1B4 and MIN6 cells were harvested when flasks reached 80% confluence or greater and were 
seeded onto 96-well plates at 2 x104 cells per well. After this, cells were incubated for 72 hours 
with 300μM or 500μM uric acid with wells of cells left untreated to act as a control. After this, the 
culture media was aspirated, the cells were washed with an assay buffer and then exposed to a dual 
detection mix consisting of the CAT dye and a dye designed to detect healthy cell nuclei. The cells 
were then incubated in the dark at 37°C for 30 minutes after which the detection mix was removed, 
and the cells were washed again with assay buffer. Following this, the level of autophagy and cell 
nuclei were determined through quantification of their respective fluorescent dyes. CAT dye 
produced fluorescence in each well was quantified via fluorescence values measured with an 
excitation/emission spectrum of 480/550nm, and nuclei were determined using excitation/emission 
350/462nm. Both were determined using a Molecular Devices® SpectraMax i3x multimode 
detection microplate reader.  
 
2.4.3 Apoptosis Assay 
The apoptosis assay is performed using the Abcam apoptosis/necrosis detection kit (ab176749). 
This uses three different dyes to quantify necrosis, apoptosis and healthy cells. It achieves this by 
taking advantage of the differing nature of the cellular processes. For apoptosis, the dye used in the 
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kit fluoresces upon binding to phosphatidylserine (PS). Under normal conditions, PS is stored 
within the cell until apoptosis begins at which point it is transferred to the cell membrane. As the 
dye used to detect apoptosis cannot enter the cell all the fluorescence that is generated by the dye 
only arises due to apoptotic expression of PS on the cell surface. In the case of necrosis, the kit 
uses a dye that only fluoresces when it encounters proteins that are only expressed within the 
nucleus. Because this dye cannot cross the membrane any fluorescence that arises due to that dye 
is because of loss of membrane integrity that is consistent with necrosis or late stage apoptosis.  
1.1B4 and MIN6 cells were harvested when the flasks reached 80% confluence or greater and were 
seeded onto 96-well plates at 2x104 cells per well. After this, cells were incubated for 72 hours 
with 300μM or 500μM uric acid with wells of cells left untreated to act as a control. Then, the 
culture media was aspirated, the cells were washed with assay buffer. Then, exposed to a detection 
mix consisting of Phosphatidylserine (PS), the kits chosen marker for early stage apoptosis, 7-
aminoactinomycin D (7-AAD) a membrane impermeable dye that marks late stage apoptosis, and 
CytoCalcein Violet 450 which detects live cells. The cells are then incubated in this detection mix 
for 30 minutes at 37°C while being protected from light to preserve the function of the fluorescent 
dyes. After this, the detection mix is removed and the cells are washed to remove any unbound 
dye. The dyes were then quantified using a Molecular Devices® SpectraMax i3x multimode 
detection microplate reader with the excitation/emission values of 490/525nm for PS, 550/650nm 
for 7-AAD and 405/450nm for CytoCalcein. 
 
2.5 RNA analysis 
2.5.1 Extraction of total RNA 
To analyse the expression of deubiquitinase RNA we first need to extract the cellular total RNA. 
1.1B4 cells were grown as previously described and total RNA was extracted using the 
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NucleoSpin® miRNA kit (Macherey-Nagel™). The extraction was performed according to the 
manufacturer’s protocol and the total RNA was eluted with 50μL of RNase free water. RNA 
concentration and purity were assessed using the Take-3 plate on a BioTek® Synergy 2 multi-mode 
microplate reader (Millennium Science™) with the target being concentration and purity exceeding 
500ng/mL and 90%, respectively. Samples were stored at -20°C until needed.  
 
2.5.2 Reverse transcription  
To allow for the gene expression to be measured using qPCR the RNA must first be converted to 
cDNA. This was done using PrimeScript™ RT reagent kit (Takara®), adhering to manufacturer’s 
protocol as shown in table 2 and table 3. 500ng of total RNA was used per sample per reverse-
transcription reaction to synthesise 500ng of cDNA. Synthesised cDNA was diluted 1:10 to 5ng/μL 
and a final volume of 100μL via adding 90μL of RNase free water (Machery-Nagel®).  
 
 
Table 2. Reverse-transcription PCR mixture 
 Component  Volume per 10μL reaction  
5x PrimeScript™ buffer  2μL  
Primescript™ RT enzyme mix  0.5μL  
Oligo dT Primer (50μM)  0.5μL  
Random 6-mers (100μM)  0.5μL  
RNase-free water  YμL (Y = 10 – (3.5 + X) 
500ng of total RNA  XμL  




Table 3. Reverse-transcription thermal cycles 
Step type  Time  Temperature (°C)  
Reverse Transcription  15 minutes  37°C  
Inactivation of RT  5 seconds  85°C  
Holding stage  ∞  4°C  
 
2.5.3 Real-time PCR  
For the preparation of the master mix for real-time PCR, 2x SYBR® Premix Ex Taq and ROX 
Reference Dye (Takara™) mix was used in conjunction with forward and reverse primers (SIGMA®) 
specific for various protein targets as listed in table 4. The thermal cycles for real-time PCR (Table 6) 
were conducted using the StepONE 96-well real-time PCR machine (Applied Biosystems®) using real-
time PCR reaction mix composition described in table 5. 
 
Table 4. List of targets and their primer sequences 
target  Primer sequence  
h18S Forward: 5’ TAACGATGCCGACTGGCGATG 3’ 
Reverse: 5’ AGACTTTGGTTTCCCGGAAGCT 3’ 
USP3 Forward: 5’ CCTCCTGAGTAGCTGGGATTA 3’ 
Reverse: 5’ CACCCTAGCCAACATGGTAAA 3’ 
OTUB1 Forward: 5’ ACCTATCTACTCCTGAGCTTCC 3’  
Reverse: 5’ AAGAAGGGAAGGAAGCAGAAC 3’ 
UCHL1 Forward: 5’ CTGGGATTTGAGGATTCAG 3’ 





Table 5. real-time PCR reaction mix composition 
Reagent  Volume (per well)  Volume (30 wells)  
SYB R® Premix Ex Taq 
(2X) plus ROX  
5μL  150μL  
10μM Forward Primer  0.4μL  12μL  
10μM Reverse Primer  0.4μL  12μL  
RNase free dH2O  2.2μL  66μL  
cDNA template (10 ng)  2μL  60μL  
Total Volume  10μL  300μL  
 
 
Table 6. qPCR thermal cycle sequences 
 Cycles  Time  Temperature  Step type  
1  2 minutes  95°C  Polymerase 
activation  
1  5 seconds  95°C  Denaturing  
40  15 seconds  60°C  Annealing/Extension  
 
2.5.4 mRNA quantification 
Relative quantification was determined based on the reference, an endogenous standard gene, (ref), 
which was 18S. This was achieved by measuring the number of cycles necessary to produce 
sufficient quantities of cDNA to pass threshold. The number of cycles was recorded for each target 
as its CT value. This was repeated using five samples for each target and the CT values were 
averaged. These average CT values were then compared to the reference gene to give a normalised 
ΔCT value as shown in the equation below. Following this, the ΔCT value for each target was 
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converted to a fold-change in expression using the second equation below to allow for the 
comparison of the target genes based on their calculated expression.    
ΔCT (UT) = CT (GOI, UT) − CT (18S, UT) 
Fold expression = 2- ΔCT
 (UT)  
 
2.6 USP3 Knockdown 
In an attempt to determine the significance of USP3’s expression on DEPTOR stability, we used a 
silencing RNA to remove USP3 in isolation to examine the effects of changing USP3 expression 
without any confounding effects. To achieve this, 1.1B4 cells were incubated in a mixture of 9µL 
lipofectamine 2000 (Thermo Fisher Scientific) and 30µL of USP3 siRNA (100pmol) (Thermo 
Fisher Scientific) or 30µL of scrambled siRNA (Thermo Fisher Scientific) to act as a control. This 
mixture was left on the cells for 24 hours before it was aspirated, and fresh media was added leaving 
the cells to grow and reach target confluence for 72 hours. Following this, the 1.1B4 cells were 
extracted and analysed using the methods previously described in 2.2.3, 2.3.1, 2.3.4, 2.3.5, and 
2.3.6. The only deviation from the previously described methodology was the use of DEPTOR as 




























3.1 General cell viability 
 
Figure 6: Changes in cell viability, metabolism and autophagy in response to 
hyperuricemic condition.  
Cells were cultured under physiological normal (300µM UA) and hyperuricemic conditions (500µM UA) for 72 
hours. Following this, live cell assays were used to perform cell viability analysis normalising to untreated cells 
(UT). 
(A) Represents total cell count and relative levels of early and late stage apoptosis in 1.1B4 cells. 
(B) Represents total cell count and relative levels of early and late stage apoptosis in MIN6 cells.  
(C) Represents cellular metabolism levels in 1.1B4 cells.  
(D) Represents cellular metabolism levels in MIN6 cells.  
(E) Represents cellular autophagy levels in 1.1B4 cells.  
(F) Represents cellular autophagy levels in MIN6 cells.  
Data is represented as mean ± SEM.  
p-values vs 300µM were calculated via Student t-test with a Tukey post-hoc analysis, p-values vs untreated cells 
were calculated using a one-way ANOVA with a Tukey post-hoc analysis. 











To initially establish, if changes in DEPTOR ubiquitination that may arise due to hyperuricemic 
conditions result in measurable changes in cell functionality and viability, we chose to measure 
multiple factors that are both critical to healthy cell function and are regulated by changes in 
DEPTOR expression. To measure changes in cellular metabolism, cellular apoptosis and 
autophagy, cells were treated with 300µM uric acid representing normal conditions, 500µM uric 
acid representing hyperuricemic condition, and PBS vehicle treated cells representing an untreated 
control over 72 hours. Following this, live cell assays were performed as outlined above in sections 
2.3, 2.4, and 2.5, respectively. 
 
3.1.1 Cellular Apoptosis  
The cell viability measure was determined by the effects of hyperuricemia on live cell count and 
the prevalence markers indicative of early and late stages of apoptosis. The live cell count of 1.1B4 
cells resulted in a statistically significant decrease down to 80% ± 6 when compared to the cells 
treated with human physiological normal conditions (Fig. 6A). In the mouse (MIN6) cells, we 
observed a statistically significant decrease down to 88% ± 2 (Fig. 6B) when compared to cells 
treated with human physiological normal conditions. In terms of early stage apoptosis, both cell 
lines trend towards an increase in apoptotic cells but neither of these trends yield a statistically 
significant result. 
E)  F)  1.1B4 MIN6 
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Finally, the late stage apoptosis marker leads to significant increases as a result of human 
hyperuricemic condition in both human (1.1B4) and mouse (MIN6) cells with the human late 
apoptotic cell response of 125% ± 5 (Fig. 6A) of the untreated and an increase of 23% compared 
to the physiological normal treated cells. The MIN6 cells exhibited a significant late apoptotic 
marker expression of 123% ± 3 (Fig. 6B) of the untreated and an increase of 21% compared to the 
cells treated under human physiological normal condition.   
3.1.2 Cellular Metabolism 
Mitochondrial metabolism is key to maintaining cellular energy. Using an MTT assay we directly 
measured the rate of cellular metabolic activity. Metabolic activity was significantly decreased 
when cells were exposed to human hyperuricemic conditions with the human cells showing a 
significant decrease compared to the cells treated with human physiological normal uric acid levels 
of 27% ± 9 (Fig. 6C) of the untreated cells. In mouse (MIN6) cells, although there was no 
significant difference between the cells treated with hyperuricemic and human physiological 
normal levels, however, both treatment groups had significantly lower cellular metabolism than 
the untreated control with human physiological normal down to 81% ± 18 and hyperuricemic 
condition down to 71% ± 28 (Fig. 6D). 
3.1.3 Cellular Autophagy 
Using the previously described autophagy assay (2.4.2) we analysed the changes in cellular 
autophagy in response to hyperuricemic conditions as shown in figures 6E and 6F. We determined 
that in both, the human and mouse cells, there was a trend towards an increased autophagy as a 
result of exposure to hyperuricemic conditions, however, this trend only proves statistically 
significant (p < 0.05) in the human cell line with relative autophagy increased by 37% ± 14 of the 
untreated control and compared to human physiological normal (300µM) condition (Fig. 6E). 
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Figure 7: Changes in DEPTOR ubiquitination in response to hyperuricemic condition. 
1.1B4 or MIN6 cells were cultured under physiological normal (300µM UA) and hyperuricemic conditions (500µM 
UA) for 72 hours. Following this, the cell lysates were used to perform a DEPTOR-based co-immunoprecipitation 
followed by western blot analysis with the resulting protein levels calculated by normalisation to DEPTOR and to 
untreated cells (UT).  
(A) Represents DEPTOR ubiquitination in 1.1B4 cells.   
(B) Represents DEPTOR ubiquitination in MIN6 cells.  
Data is represented as mean ± SEM. 
p-values vs 300µM were calculated via Student t-test with a Tukey post-hoc analysis, p-values vs untreated cells 
were calculated using a one-way ANOVA with a Tukey post-hoc analysis. 
* = p < 0.05 vs 300µM UA, # = p < 0.05 vs untreated cells (UT), ## = p < 0.01 vs untreated cells (UT), n = 4. 
 
 
Using co-immunoprecipitation, we isolated a set amount of DEPTOR from the total sample protein 
and examined the effects of hyperuricemic condition on the binding of ubiquitin as a means of 
detecting changes in the degradation signal that would be necessary to facilitate the changes in cell 
function we observed previously. Employing this isolated DEPTOR we were able to determine that 
both human and mouse cells have relatively lower levels of bound ubiquitin as a result of exposure 
to human hyperuricemic condition. In the 1.1B4 cells we were able to observe a significant 
1.1B4 Ub (46 kDa) MIN6 Ub (46 kDa) 
1.1B4 DEPTOR (46 kDa) MIN6 DEPTOR (46 kDa) 
300 µM 500 µM 300 µM 500 µM 
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decrease in ubiquitination in the cells treated under human hyperuricemic conditions when 
compared to the untreated and physiological normal condition resulting in a drop down to 64% ± 
4 (Fig. 7A) of the untreated control. 
In MIN6 cells, although the trend towards a difference between the ubiquitination of the cells 
treated under human physiological and hyperuricemic condition did not prove to be statistically 
significant. However, we did observe that both treatments exhibited a significant decrease 
compared to the untreated control with human physiological condition resulting in 37% ± 4 (Fig. 
7B) change, and with the cells exposed to hyperuricemic condition dropping down to 52% ± 7 as 




















Figure 8: Changes in regulation of DEPTOR ubiquitination in response to hyperuricemic 
condition.  
1.1B4 or MIN6 cells were cultured under human physiological normal (300µM UA) and hyperuricemic conditions 
(500µM UA) for 72 hours. Following this, cell lysates were used to perform a western blot analysis with the 
resulting protein level calculated by normalisation to GAPDH as a loading control and then to the untreated cells 
(UT).  
(A) Represents USP3 expression in 1.1B4 cells.   
(B) Represents USP3 expression in MIN6 cells.   
(C) Represents β-TrCP expression in 1.1B4 cells.  
(D) Represents β-TrCP expression in MIN6 cells.  
Data is represented as mean ± SEM. 
p-values vs 300µM were calculated via Student t-test with a Tukey post-hoc analysis, p-values vs untreated cells 
were calculated using a one-way ANOVA with a Tukey post-hoc analysis. 
 * = p < 0.05 vs 300µM UA, # = p < 0.05 vs untreated cells (UT), n = 5. 
1.1B4 β-TrCP (62 KDa) 
MIN6 β-TrCP (62 KDa) 
1.1B4 GAPDH (37 KDa) MIN6 GAPDH (37 KDa) 
300 µM 500 µM 300 µM 500 µM 
1.1B4 GAPDH (37 KDa) 
1.1B4 USP3 (59 KDa) MIN6 USP3 (59 KDa) 
MIN6 GAPDH (37 KDa)  





Once we had confirmed the change in ubiquitination of DEPTOR the next step was to analyse how 
proteins that are known to play a role in DEPTOR ubiquitination are a potential target for the 
removal of ubiquitin in response to hyperuricemic conditions. Also, we wanted to determine, if this 
change is sufficient to explain the changes we see in DEPTOR regulation. Applying western blot 
analysis, we determined that both human (1.1B4) and mouse (MIN6) cells see significant increases 
in ubiquitin specific protease 3 (USP3) expression as a result of hyperuricemic condition when 
compared to the levels of expression we see under human physiological normal conditions. Human 
cells exhibit a 35% ± 8 (Fig. 8A) increase compared to the cells treated at physiological normal. 
Additionally, this result is significantly greater than the untreated control cells being equal to 119% 
± 8 of USP3 expression under untreated condition. In MIN6 cells, we detected a less dramatic shift 
with USP3 expression trending towards an increase compared to the untreated control, however, 
this fails to reach statistical significance with the only significant difference being between the cells 
treated under human physiological conditions and those treated to hyperuricemic conditions which 
saw a comparative increase in expression equal to 27% ± 6 (Fig. 8B). 
Working in opposition to the deubiquitinating effect of USP3 is the E3 ligase β-TrCP. As with 
USP3, we investigated β-TrCP to see if the effect on ubiquitination was purely due to increased 
ubiquitin turn-over or if a reduction in initial ubiquitination was the culprit or if it was a 
combination of the two. Following this examination, we found that human and mouse cells appear 
to have differing β-TrCP responses to changing uric acid exposure. In the case of the human cells, 
β-TrCP expression significantly decreased down to 78% ± 13 (Fig. 8C) of the untreated cells when 
treated under human hyperuricemic condition, a level of 17% ± 8 lower than those treated under 
human physiological normal condition. This trend in β-TrCP was reversed in mouse cells, were we 
see a drop in β-TrCP  expression in cells under human physiological conditions down to 60% ± 6 
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of the expression presented in the untreated cells with the cells treated under human hyperuricemic 
condition reaching expression levels of 50% ± 6 greater than those of the human physiological 
normal treatment group (Fig. 8D). 
 














Figure 9: Detection of DEPTOR-bound uric acid in response to hyperuricemic condition.  
1.1B4 or MIN6 cells were cultured under human physiological normal (300µM UA) and hyperuricemic conditions 
(500µM UA) for 72 hours. Following this, cell lysates were used to perform a DEPTOR-based co-
immunoprecipitation followed by western blot analysis with the resulting protein level calculated by normalising 
to DEPTOR and to untreated cells (UT). 
(A) Represents DEPTOR-bound uric acid in 1.1B4 cells.   
(B) Represents DEPTOR-bound uric acid in MIN6 cells.  
Data is represented as mean ± SEM.  
p-values vs 300µM were calculated via Student t-test with a Tukey post-hoc analysis, p-values vs untreated cells 
were calculated using a one-way ANOVA with a Tukey post-hoc analysis. 
* = p < 0.05 vs 300µM UA, # = p < 0.05 vs untreated cells (UT), ## = p < 0.01 vs untreated cells, n = 4. 
 
 
Following the detection of USP3 and β-TrCP, the next question was, what is triggering these 
changes in DEPTOR ubiquitination and if it can’t be explained through changes in protein levels. 
To this end, we also exposed DEPTOR isolated through co-immunoprecipitation to a uric acid-
1.1B4 DEPTOR (46 kDa) 
1.1B4 UA (46 kDa) 
MIN6 UA (46 kDa) 
MIN6 DEPTOR (46 kDa)  
300 µM 500 µM 300 µM 500 µM 
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detecting antibody to investigate the possibility that uric acid may be directly binding to DEPTOR 
resulting in changes in the ubiquitination dynamic. We found that not only did we detect uric acid 
bound to DEPTOR indicating that it was acting in a manner similar to a posttranslational 
modification but that it also changed with changes in uric acid concentration. In MIN6 cells, this 
change is actual inverse to the uric acid concentration as shown in figure 9B. We revealed that not 
only is there a significant decrease in the detection of uric acid bound to DEPTOR when compared 
to the untreated control cells of down to 68% ± 4 (300µM UA) and 44% ± 6 (500µM UA), 
respectively, but also a significant difference when you compare mouse cells subjected to human 
physiological normal level. Hyperuricemic treatment of 1.1B4 cells resulted in an increase of uric 
acid-bound by 23% ± 7 (Fig. 9A) compared to untreated cells.  
In addition, human cells show a significant increase in bound uric acid under hyperuricemic 
conditions when compared to the cells under human physiological normal condition by 21% ± 8 
(Fig. 9A) of the binding found in the untreated group. It should be noted that these differences were 




3.5 Analysis of deubiquitinase expression in the 1.1B4 cells 
 
As a result of the time spent on this project new work had been published that may help to shed 
light on the nature of the mechanism we are trying to decipher. To this end, in an attempt to better 
understand the implications of recently published work investigating potential DEPTOR 
deubiquitinases, we have compared USP3 expression to deubiquitinases proposed in Zhao et al., 
2018 which were shown to have an effect on DEPTOR ubiquitination under a differing stimulus. 
We found that the primary deubiquitinase (OTUB1) proposed by Zhao et al., 2018 has a slightly 
lower but not significantly different expression when compared to USP3, however, another 
candidate that was also put forward as a one likely to be of key importance for DEPTOR regulation 
(UCHL1) was found to be significantly lower expressed when compared to both USP3 and OTUB1 
(Fig. 10).  
 
 
Figure 10: Analysis of deubiquitinase synthesis in 1.1B4 cells. 
Total RNA of 1.1B4 cells was extracted and used in qPCR experiments to determine the relative expression of 
USP3 compared to ovarian tumour domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) and ubiquitin 
carboxyl-terminal hydrolase isozyme L1 (UCHL1); Ct values were normalised to a housekeeping RNA to provide 
a baseline synthesis level. Ct Values were converted to fold expression data for the purpose of both comparison and 
display. 
Data is represented as mean ± SEM. 
p-values vs USP3 expression were calculated via Student t-test with a Tukey post-hoc analysis, p-values vs control 
RNA were calculated using a one-way ANOVA with a Tukey post-hoc analysis. 








Figure 11: USP3 knockdown.  
1.1B4 cells were treated with a USP3 siRNA to investigate the effects of isolated decreases in USP3 on DEPTOR 
expression. These cells were compared against cells treated with a random siRNA scramble which was used as a 
baseline control against the USP3 siRNA and as a control for the transfection process. 
(A) Represents USP3 expression measured by western blot 
(B) Represents DEPTOR protein levels 
Data is represented as mean ± SEM. 
p-values vs siRNA scramble were calculated via Student t-test with a Tukey post-hoc analysis.  
* = p < 0.05 vs siRNA scramble, DEPTOR: n = 4, USP3: n = 2. 
 
 
As a result of the effects observed on USP3 expression due to uric acid treatment and with the new 
insight provided by new research being published, we chose to investigate the significance of 
decreased USP3 expression in isolation to any other factor that may arise as a result of treatment 
with uric acid. To this end, we were able to run initial tests on 1.1B4 cells and although we did not 
generate sufficient data to allow for statistical analysis, the trends displayed in Figure 11A indicates 
that USP3 knock-down seemed to have been successful. In the case of DEPTOR expression, we 
found that silencing of USP3 resulted in a significant reduction of DEPTOR expression by 30% ± 












4.1 Impacts on Cellular viability and function 
Diabetes mellitus (DM) comes with specific changes in pancreatic β-cell function that denote the 
initiation or progression of T1DM or T2DM. In the case of T1DM, the initial loss of pancreatic β-
cell mass starts further irreversible loss of pancreatic function as β-cell mass continues to decrease 
in response to increased stress due to the remaining cells trying to compensate for the loss of insulin 
secretion (Jaberi-Douraki et al., 2015). In T2DM, the initial stages, although caused by the 
development of peripheral resistance to insulin signalling, leading to the loss of β-cell mass as a 
result of the stress caused by over-signalling as a compensatory mechanism to overcome the lack 
of insulin sensitivity (Rojas et al., 2018). Hence, the irreversible disease progression leads to far 
greater rates of T2DM-related complications, once patients have passed a critical point of β-cell 
mass loss (Munnee et al., 2016). These observations put the loss of β-cell mass into the spotlight 
independent of the type of DM. Thus, deciphering the molecular mechanisms of pancreatic β-cell 
mass loss is paramount. 
This study investigated the molecular mechanisms of pancreatic β-cell death based on 
hyperuricemic conditions, as high plasma uric acid levels been correlated with DM (Krishnan et 
al., 2013). Firstly, we determined that elevated extracellular uric acid levels resembling high serum 
uric acid caused significant changes in the viability and metabolic rate in both the human (1.1B4) 
and mouse (MIN6) pancreatic β-cells. These changes include a decrease in cellular metabolism 
(Fig. 6C, Fig. 6D), and live cells (Fig. 6A, Fig. 6B) which was matched with significant increases 
in apoptosis in both cell lines and autophagy in human cells (Fig. 6D). These changes indicated 
that hyperuricemic condition can create effects similar to that seen in T1DM development and 
T2DM progression. This first set of evidence is in line with existing data showing that patients with 
T2DM exhibit elevated levels of autophagy gene expression (Masini et al., 2009) caused by an 
inhibition of the main autophagy regulator, mTORC1. Furthermore, an increase in autophagy due 
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to changes in mTORC1 activity was demonstrated to have negative impacts on diabetics (Zoncu et 
al., 2011) with the damaging effects increasing over time (Bartolome & Guillén, 2014). 
These observations lead to the question of how the changes in mTORC1 activity arises and if they 
can be prevented to halt the devastating progress of β-cell mass loss. Interestingly, based on further 
evidence discussed in the following chapters we can likely link apoptotic events to the observed 
decrease in cellular metabolism as it is likely to be the initial step in the cellular response that 
results in the observed increase in apoptosis and reduction in total live cells. This idea is supported 
by the fact that starvation is known to cause this exact effect as a means of reducing the bodies’ 
energy demand through the reduction of total cell mass (He & Klionsky, 2009. Munson & Ganley, 
2015). However, this is not the full story as cells have multiple ways of adjusting themselves to 
reduced cellular metabolism before an apoptotic response is triggered. One such counter to loss of 
energy production is increasing autophagic signalling as a means of reducing cellular energy 
demand and recovering energy from unneeded proteins and organelles (He & Klionsky, 2009). 
This idea is supported by our data which shows autophagy increases significantly in 1.1B4 cells in 
response to hyperuricemic condition indicating that in addition to driving down metabolic activity 
hyperuricemic condition is also enough to trigger an increase in autophagy (Sheng et al., 2017). 
These two factors explain why we see an increase in apoptosis markers and a decrease in live cell 
counts as the reduced metabolic activity would reduce the rate of cell growth and the increased 
autophagy would trigger increased cell death. These effects would likely be sufficient to cause the 
development of DM in patients as this loss of cell mass has been linked with the formation and 
progression of DM (Pipeleers et al., 2008), and even in the cases that did not result in total β-cell 
mass loss pharmacological inhibition of the mTOR complexes has been shown to cause diabetes 
like hyperglycaemia and insulin resistance in patients (Vergès & Cariou, 2015). However, this fails 
to provide an effective target for the treatment of DM as these studies fail to provide a mechanism 
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by which hyperuricemic condition triggers these changes. To base a treatment on the fact that 
simply modulating the mTOR complexes will solve the problem without understanding this 
mechanism may have severe off target effects such as tumorigenesis as other cells are pushed into 
an abnormal growth state. A possible target to treat DM could be DEPTOR, the negative regulator 
of mTOR complexes (Catena & Fanciulli, 2017).   
 
4.2 Changes in DEPTOR regulation due to hyperuricemia 
Focusing on the fact that we detected a change in metabolic activity and autophagy in a nutrient-
independent fashion we decided to investigate if DEPTOR expression was changed in response to 
hyperuricemic conditions. It is well documented that DEPTOR is capable of modifying metabolic 
activity and autophagy within cells through its regulatory effects on the mTOR complexes (Catena 
& Fanciulli, 2017). The current literature focuses mostly on DEPTOR and its role in the 
development of cancer (Li et al., 2014) as a loss of DEPTOR function increases cell growth by 
shifting the cellular metabolism to a high energy state (Caron et al., 2017). Our previous work on 
human pancreatic β-cells (1.1B4 cells) revealed DEPTOR protein levels are increased under 
hyperuricemic conditions, which made it a prime candidate for the regulator of the changes we 
observe in cell viability. In addition, we could prove that the increase in DEPTOR protein level is 
not based on an increase in transcriptional activity (Cain, 2017). An increase in DEPTOR protein 
could also be explained by stabilising DEPTOR protein due to a change in its ubiquitination. This 
would be in line with other disease models in which DEPTOR’s stability is increased by reducing 
its ubiquitination (Wang et al., 2012). Examples include ankylosing spondylitis in which increased 
DEPTOR stability resulted in increased autophagy (Zhai et al., 2018), and in pituitary adenoma 
where increased DEPTOR stability increased autophagy and cell death (Yao et al., 2019). We can 
confirm the amount of ubiquitin bound to DEPTOR decreased significantly in mouse and human 
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pancreatic β-cells. In the human β-cells, we found a significant decrease in the cells exposed to 
hyperuricemic condition when compared to both the, untreated and physiological normal cells (Fig. 
7A). In the mouse cells, we do see significant decreases when compared to the untreated cells but 
between the human physiological normal and hyperuricemic treatment conditions we didn’t find 
the trend towards decrease to be significant, however, this is likely again due to the high uric acid 
concentrations we applied to the MIN6 cells (Fig. 7B).  
This decrease in DEPTOR ubiquitination would create effects in line with the existing literature 
where studies have shown that increased DEPTOR activity leads to decreased cellular proliferation, 
cellular metabolism and cellular growth  (Catena & Fanciulli, 2017. Li et al., 2014. Zhao et al., 
2005). In this study, we observe the trend of DEPTOR expression resulting in an inverse effect on 
cellular viability. Targeting DEPTOR expression as a means of treatment for DM is both easier 
and less likely to have off target effects as would be the case in trying to target general changes in 
cell metabolic activity or autophagy. This presents us with another question, that being what is 
responsible for the changes we observed in DEPTOR ubiquitination, and can these changes be 
reversed or modulated to act as a treatment for disturbed cell growth and viability. Although this 
does provide an answer to how the changes in cell viability and function occur, it also raises the 
question of how this change in ubiquitination is being achieved as this may provide a more specific 
treatment target or illuminate an unknown mechanism for DEPTOR protein ubiquitination. 
 
4.3 Expression of ubiquitination regulating proteins 
Firstly, we investigated the known ubiquitin E3-ligase of DEPTOR, β-TrCP (Wang et al., 2012), 
where its disturbance is known to result in pathologic changes in cellular function (Zhao & Sun, 
2012). β-TrCP protein level is significantly reduced under hyperuricemic conditions in human β-
cells (Fig. 8C) and also in mouse cells when compared to the untreated control (Fig. 8D). The 
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consequence of this down-regulation of β-TrCP under hyperuricemic conditions ultimately is less 
ubiquitination and higher DEPTOR protein stability. The impacts of this higher DEPTOR stability 
is an increase of mTOR complex inhibition and a reduction of cell growth and viability as well as 
cellular metabolism. This matches with the outcomes we would come to expect based on the 
previously discussed understanding of the consequences of changes to DEPTOR stability, 
however, this is the first study to examine the effect of uric acid on β-TrCP expression so there is 
no data with which to compare.  
In addition to the pro-ubiquitination signal generated by the E3 ligase β-TrCP, it has recently been 
shown that there are also proteins responsible for the deubiquitinating of proteins, called DUBs or 
ubiquitin specific proteases (USPs, Heideker & Wertz, 2015). This raises the need for further 
examination as this process may also be disturbed by hyperuricemic conditions which would 
further alter DEPTOR ubiquitination beyond changes in β-TrCP. If DUBs or USPs are changing 
under hyperuricemic conditions, it would limit the effectiveness of targeting β-TrCP as a treatment 
option for returning DEPTOR ubiquitination back to normal levels. As these deubiquitinating 
proteins are only a recent addition to our understanding of the protein ubiquitination dynamic, they 
are not yet well categorised or characterised (Farshi et al., 2015). At the start of this project, DUBs 
or USPs controlling DEPTOR deubiquitination were unknown. Analysis revealed USP3 as a 
potential target as it was known to be highly expressed within the pancreas (Sloper-mould et al., 
1999) and has been shown to interact with other cell proliferation targets (Fu et al., 2017). We did 
find a significant increase in the protein level of USP3 under hyperuricemic conditions in both 
human and mouse pancreatic β-cells strongly indicating that exposure to high concentrations of 
uric acid has shifted protein level to favour DEPTOR’s deubiquitination over is ubiquitination. 
This points to USP3 being key to changes we see in overall cell function and provides a potential 
target as a means of alleviating uric acids role in DM progression. This would also provide the first 
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evidence that both USP3 and potentially deubiquitinating enzymes as a whole may be regulated by 
uric acid (Fig. 8A). Although this would be the first evidence linking USP3 to uric acid the changes 
we have observed are similar to what we would expect based on the existing research has linked 
the general function of DUBs and USPs to the regulation of cellular pathways responsible for 
cellular growth, proliferation, turn over and apoptosis (Daviet & Colland, 2008). With respect to 
USP3 specifically the current literature links its expression to cellular proliferation and 
survivability through altering the stability of targets including p53 and histones (Fu et al., 2017). 
Also, studies where inhibitors have been applied to decrease USP3 function, have been shown to 
lead to runaway cell proliferation (Fu et al., 2017). The observed change in USP3 expression is in 
line with our expectation of changes in DEPTOR ubiquitination, however, it is unknown if USP3 
does in fact interact with DEPTOR. 
 
4.5 Examination of USP3 expression in the pancreas 
With previous experiments indicating that USP3 may play a major role in DEPTOR ubiquitination 
it becomes important to find ways to confirm interactions between these two proteins. To confirm 
its importance, we compared USP3 expression to OTUB1 and UCHL1. This choice was based on 
the only study on potential DEPTOR deubiquitinases which put both, OTUB1 and UCHL1, 
forward as key regulators of DEPTOR ubiquitination (Zhao et al., 2018). Zhao and co-workers 
measured different deubiquitinases as candidates for DEPTOR deubiquitination in order to 
elucidate the mechanism underlying an observed change in DEPTOR protein level in response to 
amino acid level changes. This study examined a key factor that was mirrored by our own 
investigation, demonstrating ubiquitination may be regulated by extracellular nutritional factors. 
Increasing amino acids in the culture media replicates a process which in humans can only occur 
as a result of increased uptake from dietary sources in the same way that uric acid is increased by 
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diet. Since both experiments evaluate a similar physiological trigger being extracellular nutrient 
level, it is not unreasonable to compare the mRNA expression of the published DUBs with the 
expression of USP3 in 1.1B4 cells as a means of evaluating the potential relevance of USP3’s effect 
on DEPTOR. This experiment revealed that not only is the expression of USP3 equal to that of 
OTUB1 which was selected as the most important regulator of DEPTOR ubiquitination. USP3 was 
significantly more expressed than UCHL1 which was identified as another significant regulator of 
DEPTOR (Zhao et al., 2018). These results by Zhao and co-workers can be explained by additional 
findings exhibiting that numerous deubiquitinases are capable of interacting with DEPTOR. It 
suggests that deubiquitinases have multiple targets, and that their effect is likely controlled through 
limiting their expression levels either through the effects of direct stimuli such as changes in uric 
acid, or amino acid concentrations, or due to different expression profiles in different tissue types 
such as the differing distribution we see with USP3 (Heideker & Wertz, 2015. Sloper-mould et al., 
1999). This would be supported by our investigation into USP3 expression within the pancreas as 
it showed levels equal to or significantly greater (Fig. 10) than some of the targets put forward in 
Zhao’s study. 
To further prove the significance of UPS3 we performed a targeted inhibition of USP3 through the 
use of a silencing RNA. Although we were unable to confirm the significance of the trend towards 
USP3 silencing (Fig. 11A), the strength of the trend and the resulting change in DEPTOR 
expression (Fig. 11B) makes a strong argument for its success. As a result of this experiment, we 
were able to show that the specific inhibition of endogenous USP3 in 1.1B4 significantly reduced 
the expression of DEPTOR. This result in combination with the previous evidence of USP3 
regulation by hyperuricemic conditions provides a strong case that we have identified USP3 as a 
new and major regulator of DEPTOR expression. When combined with the β-TrCP expression data 
these observations provide the first evidence for uric acid directly regulating protein ubiquitination 
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and more specifically DEPTOR ubiquitination. In addition, because  USP3 has been linked to the 
regulation of DNA damage (Lancini et al., 2014) this may also explain why we see certain cells 
having strenuous damage responses in low uric acid conditions as a result of USP3 inactivity 
creating a reduction in DNA damage detection. 
With this new understanding of the effects of USP3 and β-TrCP on DEPTOR, it raises the question 
of if the changes in β-TrCP/USP3 are the only effects mediated by elevated uric acid levels.  
 
4.6 Uric acid as a ubiquitination modifier 
With the results of previous experiments showing that hyperuricemic conditions are capable of 
modifying DEPTOR ubiquitination the question arises if this effect can be further elevated by direct 
effects of uric acid on proteins called urate-protein adducts or uratylation (Turner et al., 2018). 
Under normal conditions ubiquitination is regulated by the interaction between proteins and 
ubiquitination or deubiquitination proteins resulting in the formation of specific ubiquitin chains 
(Neutzner & Neutzner, 2012). We propose that uratylation disturbs this process. Uratylation as our 
experiment and the work of Turner and co-workers suggest is acting to interrupt the traditional 
ubiquitination process through the binding of uric acid or a modified version of it to a target protein 
in place of ubiquitin or binds to the existing ubiquitin chain modifying the length or shape thus 
modifying the interactions with proteins. The most likely region for this modification is a lysine 
residue, which is based on the fact that the vast majority of ubiquitin binding sites are lysine 
residues (Neutzner & Neutzner, 2012). Thus, it is only logical that the modifications that arise as a 
result of uric acid will share the same binding site and this has been shown in the work of Turner 
and co-workers, however, this does not exclude the potential for other binding sites. In the case of 
DEPTOR, normal ubiquitination takes the form of β-TrCP polyubiquitinating DEPTOR leading to 
its degradation (Zhao & Sun, 2012), provided that the ubiquitin chain is not removed by a 
56 
 
deubiquitinase, especially USP3. With this in mind, we chose to take the most direct route and 
examined DEPTOR for any potential direct interactions with uric acid. This would show if there 
was any direct uric acid-binding on the DEPTOR molecule as direct binding has the potential to 
inhibit interactions between ubiquitin regulating proteins by occupying the binding sites necessary 
for recognition or interaction between β-TrCP/USP3 and DEPTOR. Alternatively, detected 
DEPTOR-bound uric acid could prevent the formation of the polyubiquitin chain by binding to a 
bound-ubiquitin prematurely terminating the ubiquitin chain. This would act in a manner similar 
to the existing posttranslational modification, acetylation (Ohtake et al., 2015). Our experiment 
shows what is arguably the most interesting result being that we detected a direct binding of uric 
acid to proteins (Fig. 9A). This result demonstrates the first cell example of uric acid binding to 
protein and that this binding changes in response to changes in uric acid concentration in a way 
that is not proportional to the concertation of uric acid that the cells were exposed to. In human β-
cells exposed to hyperuricemic conditions, uratylation is significantly higher (Fig. 9A). In mouse 
β-cells, this trend is reversed with the β-cells treated with the highest levels of uric acid showing 
the lowest levels of DEPTOR bound uric acid (Fig. 9B). Both these trends indicate that instead of 
any binding detected being the result of increased random binding due to increased uric acid 
concentrations there is evidence to suggest that there is some form of regulation to the uric acid 
binding or that more than one protein is involved in the binding in the case of DEPTOR. This is 
further supported by the study by Turner and co-workers, confirming that uric acid was binding to 
ubiquitin. Uric acid adducts were analysed with mass spectrometry and with the detection of 
uratylated albumin in human serum. This study helps to reinforce our findings that detected bound 
uric acid is supporting evidence of previously unobserved protein modification. While this study 
provides proof of concept because the experiments were performed in vitro using isolated ubiquitin 
and uric acid or using patient samples, it is difficult to use these results to elucidate the underlying 
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biological regulatory mechanism. The existence of uratylation of DEPTOR or ubiquitin in vivo 
would provide an explanation for the observed correlation between hyperuricemia and diabetes as 
the bound uric acid would likely inhibit DEPTOR ubiquitination resulting in the changes we have 
previously observed in cell metabolism and viability. Furthermore, this results in the prerequisite 
decrease in pancreatic β-cell mass necessary to facilitate the development of T1DM or the 
progression of T2DM in the same way that a build-up of cytokines within a pancreatic β-cell results 
in the initiation of cell mass loss to an autoimmune response in T1DM (Rojas et al., 2018). 
 
4.7 Discussing causality, Diabetes vs hyperuricemia: 
As a result of the interconnected nature of the dietary conditions that drive the development of 
both, diabetes mellitus and hyperuricemia, questions have arisen to the nature of causality between 
the two conditions. Some have proposed that hyperuricemia can precede the development of 
diabetes mellitus and may act as a driving force towards its development (Kodama et al., 2009). 
Others, however, have proposed the rise in serum uric acid levels is simply an early indication of 
the effects of a diet that will lead to the development of diabetes mellitus independent of any 
observed changes in serum uric acid levels (Zhang et al., 2016). Due to the nature of our 
experiments we are unable to effectively determine the nature of this causality as our experiments 
are only based on increased serum uric acid in isolation to any other dietary changes.  The current 
literature shows multiple studies revealing that serum uric acid levels can act to predict the risk of 
developing diabetes mellitus (Tae et al., 2005; Soltani et al., 2013; Zhang et al., 2016; Varadaiah 
et al., 2019). This in itself indicates that there is the potential for hyperuricemia to have a causal 
effect on the development of diabetes mellitus. The literature also offers potential mechanisms that 
may provide an explanation of this effect with several studies showing that as serum uric acid levels 
increase uric acid shifts from an antioxidant to a pro-oxidant leading to changes in metabolism and 
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to the development of insulin resistance (Adnan et al., 2019). However, across the literature as a 
whole, there are studies that have shown results that minimise or dispute these effects as this is a 
controversial topic. We have chosen to look at meta-analyses of the literature which have 
concluded the current literature supports the idea of serum uric acid as an independent risk factor 
for the development of diabetes mellitus (Kodama et al., 2009). 
 
4.8 What does this mean going forward 
 Now that we have explored what the findings of this study mean both in relation to our chosen 
disease model, we would like to discuss how these potential findings may be extrapolated out to 
apply to our general understanding of physiological principles.  
The first of these will be how this study affects the understanding of uric acid and its role within 
the body. The current central dogma is that uric acid functions as both an excreted waste product 
of purine degradation (Maiuolo et al., 2016) and as an antioxidant to help overcome deficiencies 
due to the inability of humans to synthesise vitamin c (Sevanian et al., 1985). Although this study 
does not provide evidence to dispute these ideas, it does further support the idea that uric acid may 
play a larger role within the body particularly with regards to the regulation of protein level. This 
could lead to new avenues in the research of diseases that arise due to disturbances in cell growth 
regulation ranging from cancer to diabetes. A shift towards an increased focus on the importance 
of uric acid as a protein level regulator would also lead to an increase into the consideration of how 
uric acid levels may impact the dynamics of established protein regulator pathways which until 
now has seen little to no exploration. It is also worth considering that once you consider the 
importance uric acid may play on protein levels it raises the question as to how the behaviour of 
human cells may change when cultured in media with physiological normal levels of uric acid. It 
is not unreasonable to assume that the return of a substance that exists in concentrations equal to 
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300µM could significantly impact cellular function if through nothing more than altering 
concertation gradients. In addition to this, there has been some evidence to support that uric acid 
may function as a regulator of the cellular microenvironment via interacting with toll like receptors 
(Sato et al., 2009). This has been shown in some cancer studies where uric acid can act as a damage 
associated molecular pattern triggering inflammatory responses and modifying oxidative responses 
in a way that is shown to persist in tumours and neighbouring regions even after the tumour has 
been excised (Bernardes et al., 2015). 
The second way this may shift existing understanding is that these results also point to the fact that 
uric acid may be acting as a negative regulator providing an opposing signal to that generated by 
nutrients like glucose. This would be explained by the fact that under normal dietary conditions 
uric acid concentrations increase in response to starvation or excessive activity (Cicerchi et al., 
2014). Normally, it would be reasonable to assume that because the conditions under which we see 
hyperuricemia are also ones in which there is low available energy that any reduction in energy 
consuming process is due to a reduction in an activating signal. However, in our experiments we, 
have shown that despite the cells retrieving adequate levels of glucose we still see an increase in 
energy conserving pathways in the form of autophagy and mTOR inhibition. This points to the 
potential that rather than being solely due to an absence of nutrients that energy conserving 
behaviour may be also driven in part or predominantly by a uric acid build up. This effect could be 
explained in two ways: firstly, as uric acid levels are not known to fluctuate as frequently as glucose 
it may be providing a redundancy that is adapted to respond to longer term changes in energy 
availability. Secondly, this mechanism acts as a buffer to glucose stimulation by providing a 
negative feedback “break” on changes in expression that arise due to increased energy levels. This 
breaking effect would limit cellular growth signals in the cases of unstained increases in glucose 
promoting a shift towards storage over growth until a stable nutrient source can be re-established. 
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The final impact of this study, I will be speculating on is one of the most interesting but also one 
of the hardest to predict as it provides such a wide range of possibilities, and that is the indications 
that uric acid is capable of direct binding to proteins. This is shown in our uric acid co-
immunoprecipitations which indicated protein-bound uric acid (Fig. 9A, Fig. 9B), and is further 
supported by the previously referenced study by Turner and co-workers (Turner et al., 2018) which 
confirmed uric acid binding to ubiquitin in a reaction tube. This finding and new process have 
massive implications for how we think about posttranslational modification, indicating that there 
may be an entirely new form of modification which, if true, would have an incalculable impact on 
existing protein signalling pathways. Although we cannot determine the exact mechanism behind 
how uric acid binds to proteins, we can make some inferences based on the results we observed. 
The key observation is that the binding site is most likely a lysine residue shared by ubiquitin 
(Turner et al., 2018). The evidence to support this is that in humans β-cells we see a significant 
increase in uric acid binding followed by a trend towards decreasing levels of DEPTOR bound 
ubiquitin which could reasonably be assumed to be due to uric acid inhibiting ubiquitination 
through competitively binding to the same target substrate. This idea is supported by the fact that 
Turner and co-workers have shown that uric acid is capable of binding to ubiquitin which is only 
known to form bonds based on lysine targets. It is also reasonable to assume this binding between 
ubiquitin and uric acid is inhibitory to ubiquitin binding to ubiquitin in a way similar to that of 
existing acetylation resulting in the premature termination of a polyubiquitin chain (Ohtake et al., 
2015). Further support is found in the trend we see in the mouse data in which the reduction in 
bound ubiquitin approximately equals the reduction in bound uric acid (Fig. 7B, Fig. 9B) indicating 
that the uric acid detected is more likely to be bound to ubiquitin rather than DEPTOR. 
Alternatively, binding to the protein directly inhibits interactions between proteins and 
ubiquitinases in a manner similar to the interactions between phosphorylation and O-GlcNAc 
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modification (Leney et al., 2017). This would result in the kind of uric acid binding that we see in 
the human β-cells in which we see ubiquitin and uric acid binding trending inversely (Fig. 7A, Fig. 
9A) to each other indicating that uric acid binding is excluding ubiquitination. In addition to the 
impact of a new posttranslational modification, the way in which this is regulated also points to a 
potential new function of existing proteins or a new class of proteins that would be necessary to 
facilitate the binding of uric acid to its potential targets. 
 
4.9 Potential model 
As a means to visualise ideas we discussed regarding protein regulation, we have created a 
diagrammatic representation of what we believe to be the potential pathways that would result in 
the outcomes that we have observed. Firstly, figure 12 IA shows how DEPTOR is regulated under 
normal conditions, in which it is ubiquitinated by β-TrCP marking it for degradation. The first 
deviation from this is shown in figure 12 IB in which under low energy conditions DEPTOR is 
deubiquitinated (in this case by USP3) leading to the cleavage of the bound ubiquitin molecule and 
the degradation of the cleaved ubiquitin. The third case as shown in figure 12 IC is what we propose 
is happening within the mouse cells, in which the binding of uric acid to ubiquitin signalling the 
molecule for deubiquitination increasing the activity of USP3 thus preserving DEPTOR expression 
through increased ubiquitin degradation. Finally, as shown by a pathway in figure 12 II we see 
what we believe is happening in the human β-cells in which uric acid binds to the target protein in 
the same location as ubiquitin preventing the initial ubiquitination thus preserving DEPTOR 






Figure 12. Potential pathways for DEPTOR ubiquitination.  
This figure shows the proposed models of DEPTOR ubiquitination under the influence of differing uric acid 
concentrations. 
(IA) represents DEPTOR ubiquitination leading to degradation.  
(IB) represents the rescue of DEPTOR from its ubiquitination via the activity of the deubiquitinase USP3.  
(IC) represents a potential increase in DEPTOR deubiquitination as a result of uric acid binding signalling 
increased activity of USP3. 
(II) represents the inhibition of ubiquitination through the direct binding of uric acid to DEPTOR. 
 
 
4.10 Evaluating potential animal model 
For this study we chose to use two different cell lines to represent two different species, the reason 
for this is twofold. Firstly, by using multiple cell lines of different species it allows us to evaluate 
the significance of our target effects by allowing us to observe the potential for evolutionary 






      
      
         
      
  
  
      
       
  
      
  
  
       
        
      
  
  
      
       
  
       
  
           







      
  
         
      




conservation. This provides an indication of how critical the process is for overall cell function. 
Secondly, it allows us to set the groundwork for an animal model to expand from cell culture 
experiments to whole animal studies. The advantage of whole animal experiments is that it models 
the consequences of interorgan signalling and multiple pathway effects that only arise as a result 
of the interactions between different cell types. With this in mind, it is important to evaluate how 
the results we see in mouse cells and human cells differ, so that we can forecast how these 
differences may scale out to whole animal models and how these effects may translate to the 
human. Our results indicate that overall cell viability and function of the cells were similar overall 
in both, humans and mice. The points on which the cells differ can broadly be broken down into 
two categories.  
The first of these is the masking of trends in response to the hyperuricemic condition. This is best 
seen in the MIN6 cell ubiquitination data where although the human physiological normal and 
human hyperuricemic condition both show a significant decrease DEPTOR-bound ubiquitin. But, 
this is only in comparison to the untreated cells, with the resulting change being so large as to mask 
a smaller change that may be present between the human physiological normal and the human 
hyperuricemic treatment groups. This is likely because the exact cellular distribution of uricase in 
the mouse is unknown and the best model rat data does not include the pancreas within its testing 
(Motojima & Goto, 1990). As we are unable to determine if this enzyme is breaking down uric 
acid within the mouse cells potentially blunting the response to uric acid. This would reduce the 
difference between treatment groups leading to the need for a greater sample size to determine 
statistical significance. In addition to the potential blunting of the uric acid response, it could be 
possible that the difference between the mouse physiological normal serum uric acid and human 
physiological normal serum uric acid levels may be too great. This could lead to a diminishing 
returns in change to cell viability when compared to hyperuricemic conditions (estimated mouse 
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serum uric acid equals 75nmol/mL (de Azevedo et al., 2017)) as simple treating the mouse cells 
with human physiological normal uric acid may trigger a hyperuricemic response within the mouse 
pancreatic β-cells and it is unknown if the effects of hyperuricemia have a linear, exponential, or 
sigmoidal relation to uric acid concentration.  
The second major difference between human and mouse cells indicated by our experiments is the 
difference in the mechanism that underpins the changes in ubiquitination. Although we see 
significant changes in USP3 and β-TrCP, the impact of these changes is less clear as unlike the 
human the expression of both proteins seems to follow the same trend of decreasing under human 
physiological normal conditions but increasing under hyperuricemic conditions. This runs counter 
to the bound ubiquitin which is significantly decreased in both treatment groups, and which 
indicates that in the mouse cells the major diver for ubiquitination is not the expression of ubiquitin 
regulating proteins like in the human cells. As discussed previously in 4.3 and 4.4 we postulate that 
this process is instead regulated by the interactions between uric acid and ubiquitin. It shows why 
it is important to take direct measurements in protein pathway analysis. As this study shows that 
although the live cell assay indicates a similar phenotypical response to the hyperuricemic 
condition the measured protein modification levels indicate a differing mechanism which, if not 
accounted for, could lead to unexpected differences in response to targeted treatments. This 
difference in uric acid response could also explain some of the unexpected failures of certain 
treatments to translate from cell culture trails and or animal models into the clinic as uric acid is 
rarely considered in animal trials and not typically added or controlled for in cell culture media.  
With these differences in mind, we can evaluate the effectiveness of the mouse as a model for 
human hyperuricemia. In the case of the blunted response we see, this can be accounted for by 
reducing uric concentrations and treating with a uricase inhibitor. This would bring uric acid back 
towards a level more comparable to those in the humans and the treatment with uricase inhibitors 
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preventing the breakdown of uric acid allowing it to build up in a manner similar to those found in 
the human. However, as we have put forward the likely differing mechanism responsible for the 
changes we have seen, this will likely limit the potential conclusion we can draw from these 
experiments. Overall it would best be summed up that the mouse provides a potential model for 
the general changes we see under hyperuricemic condition but is unlikely to provide more in-depth 
understanding without significant modification in the form of pharmaceutical or biological 
interventions. 
4.10.1 The impact of nutrition 
As the cell lines used are representative models for two different species it is important to also 
consider how this may affect the results we have achieved. One major difference between the two 
cell lines is how the conditions necessary to induce the disease state differ from those that the cell 
would usually encounter. As both diabetes mellitus and hyperuricemia are primarily driven by 
overnutrition derived from a diet high in fats, sugars and purines it is necessary to evaluate how 
this differs from the standard diet of both models and how these standards differ between models. 
In the case of the human, this is simple as although the type of diet necessary to initiate disease 
pathogenesis is not normal, it can easily be achieved through overconsumption of normal western 
diet (Maiuolo et al., 2016). For the mouse model, however, this diet is quite different from that of 
a normal mouse. The evidence for this is the straight forward lack of diabetic or hyperuricemic 
mice found within the wild or in wild type mice (Lu et al., 2019). This points to the larger problem 
with the use of animal models in diet-based studies and that is, as a result of evolution and a typical 
diet lower in fat and protein, mice have multiple differences in the way they absorb, process and 
excrete various nutrients (National Research Council, 1989). This includes transport proteins and 
metabolic enzymes that may not only differ from those found in humans but maybe missing entirely 
in humans as is the case with the uricase enzyme which allows mice to further metabolise uric acid. 
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The impact this has on our findings is likely to be reduced as due to the nature of cellular models 
we were able to ensure that the cells were subject to the same level of uric acid exposure, however, 
this does limit the potential for extrapolation as this difference in nutrient handling provides a 
degree of uncertainty as to how accurate the replication of the human disease state really is.  
 
4.11 Limitations 
Finally, as with all things, it is important to consider potential limitations to this study to ensure 
that we do not over interpret our data and become too heavily involved in pure speculation. The 
major limitations that are unique to this study are as follows. Firstly, as all data is based on cell 
culture of non-primary cell lines this may not provide the full picture as to how these effects may 
be altered by signalling from other regions within the body such as the pancreas. A second 
limitation is that we have only used pancreatic cell lines meaning that we cannot guarantee that the 
exact same trend will be seen in other cell types which will most likely have differing levels of 
base protein level. A third limitation is purely based on the fact that there is little to no literature 
that shows exactly how concentrations of intracellular uric acid change when exposed to high 
extracellular uric acid. We know that it does cause a change in terms of a general increase, however, 
this has not been well quantified in the literature and was not quantified in this study resulting in 
potential obscuring of differences between mice and human in regards to the exact change in 
intracellular uric acid concentrations. 
 
4.12 Additional/ future experimentation 
As a final point, we would wish to discuss future experiments that we think would provide 
greater supporting evidence to our findings which, if we had greater time and budget, would have 
been performed in addition to the ones in this study. The first of these would be the use of mass 
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spectrometry analysis to confirm definitively if uric acid was binding to DEPTOR. The second 
would be to examine how the levels of intracellular uric acid concentration changed as a result of 
the hyperuricemic condition to allow us to see if this was the same in the mouse and human and 
if this provided further support for our proposed method, or if this data indicated an alternative 
possibility we were unable to see based on the data gathered. Thirdly, a more detailed analysis of 
USP3’s effects on DEPTOR through the use of overexpression via a plasmid construct and under 
expression via silencing RNA. This would allow us to definitively confirm that USP3 is 
responsible for the changes we see or if it is shown to be insufficient to explain all the changes 
we observe, and it would provide indications for a more complex signalling pathway. Lastly, we 
would like to expand the variety of cell types tested in two ways, the simplest being the use of 
additional cell types from differing regions to analyse if this is purely a local effect isolated to the 
pancreas or, more likely that this effect may be seen to varying degrees throughout the body. The 
more complex extension of this would be to use whole animal models and compare the effects of 
uric acid on DEPTOR expression in tissue samples from multiple regions within mice exposed to 
chronic hyperuricemia. This step, however, would likely be predicated on the results of initial 
cell culture-based results which would be used to provide initial expectations in both the potential 
effect and in how this compares to the effects we would expect to see in humans. 
 
4.13 Conclusion 
Finally, as we conclude this report into our findings on the effects of uric acid on DEPTOR 
ubiquitination we must refer back to our original hypothesis and evaluate if we are able to provide 
an answer to the central questions from which this study originates. Firstly, does hyperuricemia 
reduce DEPTOR ubiquitination? Here we can confirm that DEPTOR ubiquitination is reduced by 
hyperuricemia in both the mouse and human β-cells.  
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Secondly, that this change of DEPTOR ubiquitination is a result of changes to ubiquitin regulating 
protein levels. We do have evidence that shows that the expression of USP3 and β-TrCP change 
significantly under hyperuricemic conditions. The human pancreatic β-cells show a decrease in 
ubiquitination and increase in deubiquitination which both add to produce a strong DEPTOR 
stabilising effect that we observed in the reduction of DEPTOR-bound ubiquitin. In the mouse 
pancreatic β-cell, we see a similar increase in USP3 expression but under human hyperuricemic 
condition, there was a relative increase in β-TrCP which suggests a blunted response or an 
alternative mechanism that generated the reduction in DEPTOR-bound ubiquitin. Additionally, we 
were able to find the first strong evidence that USP3 is a major regulator of DEPTOR 
deubiquitination.  
On the third aspect of our hypothesis, regarding the direct binding of uric acid to DEPTOR, we 
originally hypothesised that we would not see any direct uric acid binding as at the time there was 
no existing data to support this idea; and it was less likely that a new type of protein modification 
would be suggested by this study instead of some indirect interference of uric acid based on its 
established role as an anti-oxidant. This, however, was demonstrated to be false by both our own 
work in which we were able to detect protein-bound uric acid in both human and mouse pancreatic 
β-cells, and by data published by another group over the course of this study.  
Lastly, we also put forward the idea that as a result of the changes in DEPTOR ubiquitination we 
expected to see, we would also expect to see changes in cell viability favouring decreased viability 
and function to which we saw results that would be largely in line with what we would expect, a 
decrease in metabolic activity, and β-cell count paired with an increase in apoptosis even if the 
response in the mouse cells was slightly blunted.  
Finally, we would like to present our closing thoughts on this study: we believe that these study 
results make a strong argument for uric acid being able to modify the ubiquitination of DEPTOR 
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and that USP3 plays a major role in the regulation of DEPTOR deubiquitination. We hope that this 
will spark further research into a topic that has been largely ignored and may provide many 
potential benefits and opportunities for improvement of existing understanding, medical practices, 
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Appendix 1. Expanded western blots. 
Expanded protein band and ladder. In the case of some blots, the ladder is shared. 
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